{"meta":{"query_hash":"c17a046801e7","filters":{"venue":"Therapeutic Advances in Neurological Disorders"},"cohort_total":60,"direct_labels_cover":0,"predictions_cover":60,"exported":60,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c17a046801e7","api":"https://metacan.xera.ac/api/v1/cohort?venue=Therapeutic+Advances+in+Neurological+Disorders"},"results":[{"id":"W145182321","doi":"10.1177/1756285608098359","title":"Review: Escalating immunotherapy of multiple sclerosis","year":2008,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Natalizumab; Glatiramer acetate; Alemtuzumab; Multiple sclerosis; Mitoxantrone; Immunotherapy; Clinical trial; Disease; Intensive care medicine; Fingolimod; Oncology; Immunosuppression; Immunology; Internal medicine; Transplantation; Chemotherapy; Immune system","score_opus":0.08269379223139042,"score_gpt":0.33855184917256637,"score_spread":0.2558580569411759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W145182321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010422757,0.99699676,0.00009759401,0.000629786,0.0011710477,0.00004148766,0.000028065795,0.000007294165,0.0009237976],"genre_scores_gemma":[0.00073309353,0.996406,0.0002582238,0.0012739564,0.0006951428,0.00003765034,0.000039446233,0.0000020671166,0.0005543674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99885285,0.00041649913,0.00024125219,0.0001073082,0.0003434868,0.00003851537],"domain_scores_gemma":[0.9982811,0.0010146289,0.00028842638,0.00003385517,0.00029549468,0.00008648865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015903225,0.0012434486,0.0028743302,0.0023742781,0.00034273328,0.0015334075,0.0015216115,0.001971192,0.006886983],"category_scores_gemma":[0.004078671,0.00027840497,0.0008677556,0.003612505,0.00063033745,0.0017367259,0.00053131214,0.0015724644,0.0024742363],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045825163,0.00008156672,0.00020385702,0.1140427,0.000638461,0.00035019557,0.00006610397,0.00036061628,0.00071298087,0.0012020542,0.13025296,0.7516302],"study_design_scores_gemma":[0.00038907127,0.0003863949,0.0021596127,0.053652965,0.0014283168,0.0026100879,0.000120842524,0.00013365236,0.0004191344,0.001973945,0.93669045,0.00003557799],"about_ca_topic_score_codex":0.0013294391,"about_ca_topic_score_gemma":0.0023328587,"teacher_disagreement_score":0.006886983,"about_ca_system_score_codex":0.0011338628,"about_ca_system_score_gemma":0.0014999621,"threshold_uncertainty_score":0.023039281},"labels":[],"label_agreement":null},{"id":"W1969905648","doi":"10.1177/1756285609336548","title":"Implementation of computer-based language therapy in aphasia","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Neurobiology of Language and Bilingualism","field":"Neuroscience","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Stroke Network","keywords":"Aphasia; Medicine; Intervention (counseling); Comprehension; Speech therapy; Audiology; Psychiatry; Linguistics","score_opus":0.022293370639712522,"score_gpt":0.34921015492106594,"score_spread":0.3269167842813534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969905648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99744475,0.00010499928,0.00068708387,0.000062165476,0.000007619306,0.00050379714,0.00002084448,0.00003577538,0.0011329048],"genre_scores_gemma":[0.9943506,0.00016982516,0.0039486308,0.00006343677,0.000008627822,0.0005432001,0.000081733226,0.00000392465,0.00083004433],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9993476,0.00026748053,0.00006563025,0.00010196644,0.00009611281,0.00012119235],"domain_scores_gemma":[0.9990727,0.00029322619,0.000089448644,0.00012864583,0.00013898926,0.00027704253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083713187,0.00032978342,0.00033925587,0.00046133113,0.0006038958,0.00035566368,0.00040491336,0.00040675318,0.0016126988],"category_scores_gemma":[0.003477079,0.00009416744,0.0002200228,0.00028545453,0.00042601614,0.0003525537,0.0007847,0.00040769184,0.00022081535],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040844325,0.04308816,0.047335424,0.00053970865,0.00014413486,0.0009596201,0.0072166063,0.0024794561,0.03329202,0.0004097825,0.0008335106,0.8596171],"study_design_scores_gemma":[0.00590756,0.22004035,0.7145845,0.00032329245,0.00050797616,0.0034071007,0.005175223,0.0059995377,0.02690419,0.0015243798,0.015508721,0.0001170565],"about_ca_topic_score_codex":0.0035908476,"about_ca_topic_score_gemma":0.007391233,"teacher_disagreement_score":0.0035908476,"about_ca_system_score_codex":0.00064993143,"about_ca_system_score_gemma":0.0017753621,"threshold_uncertainty_score":0.007139921},"labels":[],"label_agreement":null},{"id":"W2050439782","doi":"10.1177/1756285608101378","title":"Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Dopaminergic; Dopamine; Levodopa; Medicine; Neuroscience; Parkinson's disease; Stimulation; Dopamine receptor; Dopaminergic pathways; Disease; Pharmacology; Psychology; Internal medicine","score_opus":0.022206452307059622,"score_gpt":0.3253167809701142,"score_spread":0.30311032866305454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050439782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041838852,0.9926069,0.00041709436,0.0011288585,0.0008466867,0.000018280898,0.0000345992,0.000022032875,0.0045072534],"genre_scores_gemma":[0.0046073394,0.9867909,0.0013559196,0.0015171624,0.0015814435,0.00003880126,0.00008221405,0.000009130304,0.00401698],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980205,0.00007049562,0.000034332745,0.000019216433,0.00005782095,0.000016111378],"domain_scores_gemma":[0.9997335,0.00014479696,0.000040121213,0.0000070975825,0.0000429836,0.00003142457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040232716,0.0007882501,0.0009569086,0.0013626842,0.00031713335,0.0006619336,0.0006488975,0.0010688183,0.012566534],"category_scores_gemma":[0.0006647228,0.00014256964,0.00038135608,0.0010335117,0.00035874092,0.0009583443,0.000369194,0.001133265,0.005766605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023096665,0.00016307352,0.00018402048,0.010828818,0.00007332188,0.0013883045,0.000055905337,0.00016141517,0.004236683,0.0014428011,0.09430276,0.8869319],"study_design_scores_gemma":[0.00011891942,0.00028370038,0.0011686464,0.0025496462,0.00016227656,0.009713968,0.00007781475,0.00008603948,0.0013677711,0.0011876683,0.98326564,0.000017945196],"about_ca_topic_score_codex":0.00035880058,"about_ca_topic_score_gemma":0.0008529397,"teacher_disagreement_score":0.012566534,"about_ca_system_score_codex":0.0002877443,"about_ca_system_score_gemma":0.00044639368,"threshold_uncertainty_score":0.042039275},"labels":[],"label_agreement":null},{"id":"W2085475081","doi":"10.1177/1756285609102724","title":"Review: Therapy for Alzheimer's disease: how effective are current treatments?","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Memantine; Medicine; Tolerability; Disease; Rivastigmine; Alzheimer's disease; Cholinesterase; Neurotransmitter receptor; Intensive care medicine; Pharmacology; Donepezil; Internal medicine; Dementia; Receptor; Adverse effect","score_opus":0.03884627347654957,"score_gpt":0.3714684075139778,"score_spread":0.33262213403742824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085475081","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005969391,0.9977354,0.000044354696,0.0012993066,0.0005358015,0.000016242286,0.00003717513,0.0000039387237,0.00026811802],"genre_scores_gemma":[0.0012212129,0.99645567,0.00014553449,0.0014671145,0.00044709427,0.00002582518,0.000030933377,0.0000017815431,0.00020487142],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9988142,0.00054704014,0.00023365811,0.00008881874,0.0002776768,0.00003863159],"domain_scores_gemma":[0.9967169,0.0021721374,0.00046912927,0.000042782485,0.00047893965,0.000120086035],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00207456,0.0013066834,0.0060861777,0.0023256075,0.00046047,0.0017915325,0.0014629965,0.003103371,0.0066326126],"category_scores_gemma":[0.0099757025,0.00034849875,0.0016662134,0.0040634456,0.000794194,0.002167893,0.00051208533,0.0016539554,0.0015766713],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007312793,0.00004585945,0.00035273688,0.31448156,0.0026651877,0.0002474672,0.000101601494,0.00038884836,0.00033658615,0.0014373229,0.13756008,0.54165155],"study_design_scores_gemma":[0.00079231506,0.00040266637,0.004824827,0.37107384,0.015517274,0.0013705423,0.00043917936,0.00029587993,0.00034530103,0.0054459404,0.59941477,0.00007739172],"about_ca_topic_score_codex":0.0035115236,"about_ca_topic_score_gemma":0.008317316,"teacher_disagreement_score":0.0066326126,"about_ca_system_score_codex":0.0014642774,"about_ca_system_score_gemma":0.0026019649,"threshold_uncertainty_score":0.022188365},"labels":[],"label_agreement":null},{"id":"W2103958324","doi":"10.1177/1756285611406166","title":"Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; University of Toronto; Centre for Addiction and Mental Health","funders":"Universidad de Buenos Aires; Consejo Nacional de Investigaciones Científicas y Técnicas","keywords":"Melatonin; Neuroprotection; Parkinson's disease; Medicine; Substantia nigra; Agomelatine; Circadian rhythm; Disease; Neuroscience; Melatonin receptor; REM sleep behavior disorder; Sleep (system call); Pharmacology; Internal medicine; Psychology; Hippocampus; Antidepressant","score_opus":0.024218408577794403,"score_gpt":0.252517391484598,"score_spread":0.22829898290680362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103958324","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08669518,0.9005876,0.0022148322,0.0024549898,0.00049306254,0.00006130682,0.00007201154,0.000075575204,0.0073454618],"genre_scores_gemma":[0.40408075,0.5837292,0.004047891,0.0011304424,0.0010268588,0.00008704508,0.00013180569,0.000019669646,0.005746329],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99996436,0.000013201939,0.0000029672747,0.000006428235,0.0000059885006,0.0000070688807],"domain_scores_gemma":[0.99996567,0.000010534282,0.00000926879,0.0000022499028,0.0000049501573,0.000007225531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002359139,0.00029919075,0.00042913298,0.0003653061,0.0001537256,0.00024787936,0.00027460622,0.0005644167,0.0015678336],"category_scores_gemma":[0.000113928516,0.00006298211,0.00027938857,0.00023526857,0.00019888423,0.0003447799,0.0001804339,0.000616588,0.00024440564],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035308334,0.00097185,0.00075965404,0.0029689348,0.00012570726,0.0010694389,0.00014777268,0.00067476294,0.23927605,0.006544017,0.003738303,0.74019265],"study_design_scores_gemma":[0.0028183898,0.058764033,0.02254321,0.0013471032,0.0008061242,0.009220101,0.00040242352,0.0030241162,0.23866495,0.013232348,0.649054,0.00012316713],"about_ca_topic_score_codex":0.00022301966,"about_ca_topic_score_gemma":0.00075179373,"teacher_disagreement_score":0.0015678336,"about_ca_system_score_codex":0.00017312831,"about_ca_system_score_gemma":0.00015381974,"threshold_uncertainty_score":0.0052449703},"labels":[],"label_agreement":null},{"id":"W2131043834","doi":"10.1177/1756285613476127","title":"Diagnosis and treatment of impulse control disorders in patients with movement disorders","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Impulse control; Medicine; Movement disorders; Impulsivity; Psychiatry; Parkinson's disease; Amantadine; Parkinsonism; Impulse control disorder; Antipsychotic; Disease; Internal medicine; Pathological; Schizophrenia (object-oriented programming)","score_opus":0.007107237729423374,"score_gpt":0.24302662833616773,"score_spread":0.23591939060674436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131043834","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72650653,0.1808625,0.0028994537,0.017982746,0.00096363004,0.00077998894,0.0006825475,0.00021215182,0.0691103],"genre_scores_gemma":[0.9451862,0.040190946,0.0043289782,0.0037021092,0.0010439677,0.00031407652,0.00065187615,0.000012608478,0.004569176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9997273,0.00009865752,0.00005203837,0.000024583482,0.000056840632,0.00004046218],"domain_scores_gemma":[0.9996768,0.00007642378,0.00009757827,0.000010854476,0.00004371289,0.00009455221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033891722,0.0001475157,0.00045314964,0.0004684716,0.000448484,0.00033529545,0.00021517888,0.0005553124,0.0018672859],"category_scores_gemma":[0.0015025187,0.00008665751,0.0003677213,0.0003756962,0.0001459498,0.0002598406,0.00025137773,0.0006272006,0.00038203108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001919741,0.0030263693,0.27373526,0.0011729978,0.00016934982,0.0065464284,0.00054355914,0.00028460656,0.0025188536,0.00090467796,0.0138442,0.69533396],"study_design_scores_gemma":[0.001480902,0.006386878,0.90174323,0.0018852901,0.00040277038,0.029269746,0.0010718788,0.0009914057,0.0018279018,0.0020649363,0.0528115,0.000063557396],"about_ca_topic_score_codex":0.0013517143,"about_ca_topic_score_gemma":0.0030114083,"teacher_disagreement_score":0.0018672859,"about_ca_system_score_codex":0.0004292719,"about_ca_system_score_gemma":0.00072162674,"threshold_uncertainty_score":0.0062467456},"labels":[],"label_agreement":null},{"id":"W2163670346","doi":"10.1177/1756285610391693","title":"Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Multiple sclerosis; Expanded Disability Status Scale; Internal medicine; Interferon beta-1a; Placebo; Randomized controlled trial; Gastroenterology; Quartile; Confidence interval; Interferon beta; Immunology; Pathology","score_opus":0.1420817650018123,"score_gpt":0.3665192244154442,"score_spread":0.2244374594136319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163670346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99842346,0.00077034277,0.00014323332,0.00004386952,0.000008210256,0.000027488028,0.00036093825,0.000004575539,0.00021791185],"genre_scores_gemma":[0.99920696,0.00008622404,0.00008858562,0.00003252986,0.000020387306,0.000036552687,0.00044323277,0.0000024000556,0.00008310508],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99380314,0.0041632676,0.00038164726,0.00060032663,0.0007177781,0.00033382222],"domain_scores_gemma":[0.98809904,0.005763362,0.0038285176,0.000972056,0.0004663433,0.00087067916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007900273,0.00058180577,0.0012541877,0.00048582035,0.0003100327,0.00074990443,0.0006442856,0.00066850416,0.0015118604],"category_scores_gemma":[0.008503311,0.000251529,0.0028683108,0.00060844695,0.00043182904,0.0007101277,0.0009002635,0.001322669,0.00014263653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10807606,0.001067372,0.8669284,0.00028869484,0.01037991,0.0002381468,0.00020312391,0.00077266514,0.001292818,0.00005222443,0.0002767031,0.010424054],"study_design_scores_gemma":[0.0013598904,0.011141778,0.98423856,0.000020858344,0.0018685571,0.00012450175,0.000093206254,0.0005987317,0.00024103347,0.00006320469,0.00023120616,0.000018528703],"about_ca_topic_score_codex":0.00059717626,"about_ca_topic_score_gemma":0.0006540081,"teacher_disagreement_score":0.007900273,"about_ca_system_score_codex":0.0003085545,"about_ca_system_score_gemma":0.00040990944,"threshold_uncertainty_score":0.041781127},"labels":[],"label_agreement":null},{"id":"W2167117206","doi":"10.1177/1756285614546855","title":"Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects","year":2014,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Fungal Plant Pathogen Control","field":"Agricultural and Biological Sciences","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Tolerability; Context (archaeology); Clinical trial; Intensive care medicine; Relapsing remitting; Alternative medicine; Investigational Drugs; Adverse effect; Pharmacology; Internal medicine; Fingolimod; Immunology; Pathology","score_opus":0.06633268888999329,"score_gpt":0.29722541186729146,"score_spread":0.23089272297729818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167117206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000092457936,0.99934095,0.000043845266,0.00012554677,0.0000610802,0.0000022445295,0.0000083838795,0.0000027713438,0.0003227016],"genre_scores_gemma":[0.00046536265,0.999158,0.00010169521,0.00007634465,0.000064221174,0.0000026786906,0.000009663518,5.1526047e-7,0.00012153692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99984646,0.000028579112,0.00003189447,0.00002640095,0.00005217457,0.000014375894],"domain_scores_gemma":[0.9996959,0.00016113612,0.00005297579,0.0000066455755,0.000058808884,0.000024528474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059619354,0.000593386,0.0011874909,0.0019119894,0.00023428969,0.0008900915,0.00066144177,0.00088010164,0.0036111837],"category_scores_gemma":[0.0006487018,0.00018256095,0.00046026445,0.0020675135,0.00036089972,0.0010614388,0.0005333336,0.0013239476,0.0013625174],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001245707,0.0000794235,0.0001620513,0.023842255,0.00010595059,0.00020212473,0.000059339956,0.00020690614,0.0017366833,0.0017275666,0.011035373,0.96071774],"study_design_scores_gemma":[0.00005213508,0.00022950683,0.0014323782,0.010398606,0.00041839312,0.0020263637,0.00014138197,0.00012457,0.00079942436,0.002341187,0.98201054,0.000025447456],"about_ca_topic_score_codex":0.0007497843,"about_ca_topic_score_gemma":0.0015037354,"teacher_disagreement_score":0.0036111837,"about_ca_system_score_codex":0.0003468,"about_ca_system_score_gemma":0.00086895376,"threshold_uncertainty_score":0.01208061},"labels":[],"label_agreement":null},{"id":"W2168568690","doi":"10.1177/1756285614549554","title":"Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome","year":2014,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Bayer HealthCare","keywords":"Medicine; Multiple sclerosis; Clinically isolated syndrome; Interferon beta-1b; Placebo; Expanded Disability Status Scale; Magnetic resonance imaging; Internal medicine; McDonald criteria; Randomization; Clinical trial; Interferon beta-1a; Interferon beta; Gastroenterology; Pathology; Immunology; Radiology","score_opus":0.2568097306530227,"score_gpt":0.4393229827033321,"score_spread":0.18251325205030938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168568690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018948813,0.99951756,0.000011796701,0.00007103474,0.000029659534,0.0000052471296,0.000015353904,0.0000013238536,0.00015859542],"genre_scores_gemma":[0.0022529222,0.99743855,0.000071543596,0.00011149217,0.000025340483,0.0000080138425,0.000025974932,6.819632e-7,0.000065586755],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99951077,0.00017467287,0.000133238,0.00005074769,0.00011097377,0.000019634736],"domain_scores_gemma":[0.99818146,0.0012603472,0.00030145596,0.000025182604,0.00018437725,0.00004732987],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019133169,0.0006132681,0.0023611686,0.001728314,0.00016696072,0.0007165467,0.00092894625,0.0009209048,0.0033991751],"category_scores_gemma":[0.0029714522,0.00031356653,0.0012857137,0.0021258672,0.0004101211,0.00052441336,0.0004478039,0.0008777798,0.0005083556],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001820277,0.00009095567,0.00040526048,0.2697361,0.0029879739,0.00015608993,0.00009282713,0.00015982562,0.0012160649,0.0011968133,0.009629086,0.7125087],"study_design_scores_gemma":[0.0028999983,0.0024934688,0.016548783,0.27110848,0.036824178,0.0028423725,0.0004145278,0.0003278414,0.0030161566,0.0027809702,0.66064465,0.000098611265],"about_ca_topic_score_codex":0.0015910737,"about_ca_topic_score_gemma":0.002616241,"teacher_disagreement_score":0.0033991751,"about_ca_system_score_codex":0.0005866938,"about_ca_system_score_gemma":0.001458068,"threshold_uncertainty_score":0.0113713145},"labels":[],"label_agreement":null},{"id":"W2405578566","doi":"10.1177/1756285616648060","title":"Quantitative analysis of multiple sclerosis patients’ preferences for drug treatment: a best–worst scaling study","year":2016,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of Saskatchewan; Sunnybrook Hospital; Memorial University of Newfoundland; University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Multiple sclerosis; Drug; Preference; Latent class model; Logistic regression; Pharmacotherapy; Intensive care medicine; Internal medicine; Pharmacology; Psychiatry; Machine learning; Statistics","score_opus":0.12485522937899911,"score_gpt":0.37362392206675404,"score_spread":0.24876869268775492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405578566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99854666,0.000047122227,0.0005194369,0.000068778485,0.0000019880995,0.000054193762,0.00012872287,0.0000017717026,0.000631226],"genre_scores_gemma":[0.9993513,0.000019317054,0.0004256806,0.000017355142,0.0000015577855,0.000036315523,0.00008096605,8.270425e-7,0.00006661026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538165,0.0028216934,0.00035389198,0.000273142,0.00091026584,0.0002594584],"domain_scores_gemma":[0.9807566,0.011339852,0.0040378,0.0008630611,0.002075805,0.00092689815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0076907407,0.00024039591,0.00042469468,0.00079050486,0.0008473344,0.0011174136,0.00031621524,0.0002930737,0.00238698],"category_scores_gemma":[0.022949671,0.00012199194,0.0009921886,0.0010650961,0.0011172423,0.0006544184,0.000753584,0.00056133186,0.00011058333],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013881739,0.00043176315,0.9475869,0.00016677185,0.0005227926,0.00013024671,0.01354962,0.001430005,0.0011593695,0.00086114224,0.00073167775,0.03204163],"study_design_scores_gemma":[0.00012466703,0.0010139463,0.9640839,0.000075661985,0.00014904207,0.00022048826,0.023971917,0.006911744,0.0005178723,0.0012506279,0.001604608,0.0000755106],"about_ca_topic_score_codex":0.021941517,"about_ca_topic_score_gemma":0.027190061,"teacher_disagreement_score":0.021941517,"about_ca_system_score_codex":0.0026301877,"about_ca_system_score_gemma":0.0014343761,"threshold_uncertainty_score":0.04362762},"labels":[],"label_agreement":null},{"id":"W2737414819","doi":"10.1177/1756285617722352","title":"Liver injury and glatiramer acetate, an uncommon association: case report and literature review","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Drug-Induced Hepatotoxicity and Protection","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alberta Innovates - Health Solutions; Biogen; Sanofi","keywords":"Medicine; Glatiramer acetate; Autoimmune hepatitis; Discontinuation; Liver injury; Magnetic resonance imaging; Liver function; Lesion; Multiple sclerosis; Liver biopsy; Past medical history; Hepatitis; Radiology; Gastroenterology; Internal medicine; Surgery; Biopsy; Immunology","score_opus":0.17526836751665378,"score_gpt":0.49953015378177357,"score_spread":0.3242617862651198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737414819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002302744,0.9956392,0.0001627564,0.000309056,0.00018389468,0.000008225405,0.00003633031,0.000013714375,0.0013441261],"genre_scores_gemma":[0.01658749,0.9811288,0.00040034225,0.00046903905,0.00083284103,0.000010301155,0.000093981165,0.000005127032,0.0004720537],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.9996865,0.000040519066,0.00011837257,0.00006127177,0.000060600738,0.000032715194],"domain_scores_gemma":[0.9990553,0.00040575804,0.00033372067,0.000038144004,0.00010157891,0.00006547004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047013,0.0008652614,0.0010899735,0.0047268146,0.000569811,0.0012156431,0.00087311893,0.0013848738,0.0026226481],"category_scores_gemma":[0.0011280355,0.00032978843,0.0004859311,0.004390698,0.0006854466,0.0017510076,0.0007759912,0.00092465244,0.0010605742],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015428764,0.00021796716,0.014285345,0.041251563,0.00044438333,0.16960266,0.00090875267,0.0005343611,0.0037157796,0.0024271384,0.040749706,0.72570795],"study_design_scores_gemma":[0.000024458977,0.00010116813,0.009538295,0.008767312,0.0005654206,0.70763755,0.00079149404,0.0001701031,0.000888968,0.0017921831,0.26966622,0.000056771943],"about_ca_topic_score_codex":0.0009491023,"about_ca_topic_score_gemma":0.0016542801,"teacher_disagreement_score":0.0047268146,"about_ca_system_score_codex":0.000329455,"about_ca_system_score_gemma":0.0010863878,"threshold_uncertainty_score":0.008773565},"labels":[],"label_agreement":null},{"id":"W2804885025","doi":"10.1177/1756286418774338","title":"Phase IV study of retention on fingolimod <i>versus</i> injectable multiple sclerosis therapies: a randomized clinical trial","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fingolimod; Medicine; Multiple sclerosis; Randomized controlled trial; Natalizumab; Relapsing remitting; Clinical trial; Internal medicine; Oncology; Immunology","score_opus":0.1835123173007922,"score_gpt":0.42967258634070865,"score_spread":0.24616026903991645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804885025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97902244,0.002508364,0.0011885035,0.00085693685,0.0007777526,0.012335679,0.001196843,0.00019700048,0.0019165501],"genre_scores_gemma":[0.9707587,0.0023600582,0.0036559624,0.0019522693,0.0011330829,0.015329236,0.0014284292,0.000054967193,0.003327392],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983144,0.0010438947,0.00009378723,0.0002613131,0.000117253156,0.00016945301],"domain_scores_gemma":[0.99754745,0.0007956634,0.0006210423,0.00021850111,0.00017925208,0.0006381499],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004811453,0.0021095583,0.0035448421,0.0005034035,0.00057383976,0.0013458765,0.0012371801,0.0023316648,0.0072031314],"category_scores_gemma":[0.0030519064,0.00088630425,0.0019113355,0.00047873426,0.0015404086,0.0011508623,0.00047817806,0.0031636276,0.0012818878],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9837496,0.008513383,0.00028042006,0.00023697592,0.00044779296,0.000016758919,0.00002811252,0.00014570577,0.0016733599,0.00004919392,0.00033661592,0.004522165],"study_design_scores_gemma":[0.9526385,0.04591533,0.00048099167,0.000013984719,0.00017127108,0.000012331389,0.0000067574815,0.00027621133,0.00020338052,0.000060167404,0.00021424307,0.000006808215],"about_ca_topic_score_codex":0.0006865858,"about_ca_topic_score_gemma":0.0009989005,"teacher_disagreement_score":0.0072031314,"about_ca_system_score_codex":0.0008004348,"about_ca_system_score_gemma":0.001644527,"threshold_uncertainty_score":0.0254457},"labels":[],"label_agreement":null},{"id":"W2889307958","doi":"10.1177/1756286418791143","title":"Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McGill University; London Health Sciences Centre; NeuroRx Research (Canada)","funders":"Genentech; Biogen","keywords":"Medicine; Tolerability; Multiple sclerosis; Dosing; Adverse effect; Clinical endpoint; Internal medicine; Incidence (geometry); Surgery; Clinical trial","score_opus":0.12081327884060752,"score_gpt":0.3691826571197619,"score_spread":0.24836937827915437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889307958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938769,0.0035162321,0.00015514003,0.00015048121,0.000024398958,0.00018741285,0.00093124236,0.00002046885,0.0011377624],"genre_scores_gemma":[0.9945627,0.0011455442,0.00038918163,0.00020190576,0.00014063726,0.00020670857,0.002540001,0.000006424394,0.00080689817],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9993248,0.0003248002,0.0000799979,0.000077181765,0.00012965464,0.000063562504],"domain_scores_gemma":[0.9974542,0.00040302996,0.0010522056,0.00021337747,0.0002041006,0.0006731573],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004290654,0.0005276642,0.00083239825,0.00025827248,0.00028673184,0.0004978934,0.00029476822,0.0005986922,0.0017042527],"category_scores_gemma":[0.00204385,0.000160208,0.0009991722,0.00025726485,0.00034821563,0.0005782714,0.0005037087,0.0010158946,0.0002892444],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.76135534,0.018307118,0.09966913,0.0012185627,0.003195519,0.00041162476,0.00044687325,0.0018448076,0.011078271,0.00023364686,0.0039286204,0.098310485],"study_design_scores_gemma":[0.153283,0.29858488,0.5313931,0.00031888857,0.0032341168,0.0011071922,0.00014858454,0.0010625494,0.0027730262,0.00028519594,0.0077415435,0.000067923174],"about_ca_topic_score_codex":0.000271128,"about_ca_topic_score_gemma":0.0004827158,"teacher_disagreement_score":0.004290654,"about_ca_system_score_codex":0.00027324946,"about_ca_system_score_gemma":0.00040206336,"threshold_uncertainty_score":0.022691429},"labels":[],"label_agreement":null},{"id":"W2889527974","doi":"10.1177/1756286418795085","title":"Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Biogen","keywords":"Medicine; Multiple sclerosis; Predictive value; Clinical disease; Magnetic resonance imaging; Internal medicine; Disease; Cardiology; Gastroenterology; Radiology; Immunology","score_opus":0.06831757290086274,"score_gpt":0.3485683056196654,"score_spread":0.28025073271880263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889527974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99827576,0.0010872586,0.000068101675,0.000047010257,0.000015855561,0.00003493639,0.00008797232,0.000007244661,0.0003758309],"genre_scores_gemma":[0.9986959,0.00035829173,0.00025144347,0.000049986505,0.000042163003,0.000037592723,0.00019403566,0.0000020218256,0.00036854995],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9993082,0.00035966118,0.000060972397,0.000114590905,0.000092391456,0.00006409077],"domain_scores_gemma":[0.99830925,0.00040186703,0.00070513086,0.00013144192,0.00009762394,0.00035467805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024088763,0.0005494305,0.0011795841,0.00025528934,0.0001729585,0.00052724086,0.00021536896,0.00046886678,0.0010263397],"category_scores_gemma":[0.0019984962,0.0002643419,0.001018566,0.00024238668,0.0002902826,0.0006821992,0.000553015,0.0011102288,0.0001068082],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.73615825,0.007979833,0.1482288,0.0007522194,0.0024817807,0.00027966563,0.00055113167,0.0019829778,0.024507135,0.0002260242,0.0010272202,0.07582493],"study_design_scores_gemma":[0.051803675,0.33785918,0.5926143,0.00012956357,0.0029302444,0.0007597327,0.00018472811,0.0026999055,0.006277531,0.00026604094,0.0043855254,0.00008957966],"about_ca_topic_score_codex":0.000326668,"about_ca_topic_score_gemma":0.0008125714,"teacher_disagreement_score":0.0024088763,"about_ca_system_score_codex":0.00031190223,"about_ca_system_score_gemma":0.0003062101,"threshold_uncertainty_score":0.012739539},"labels":[],"label_agreement":null},{"id":"W2899137047","doi":"10.1177/1756286418804760","title":"Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novartis Pharma; IC Design Education Center; Biogen; Ipsen; Novartis","keywords":"Fingolimod; Medicine; Multiple sclerosis; Pregnancy; Natalizumab; Intensive care medicine; Internal medicine; Immunology","score_opus":0.01914898633168949,"score_gpt":0.26108031739118004,"score_spread":0.24193133105949055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899137047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954852,0.0017125702,0.0004400042,0.000118355514,0.000008776194,0.000059175698,0.0007138619,0.00001117373,0.0014509369],"genre_scores_gemma":[0.99783725,0.00075963547,0.0005241647,0.000044561733,0.000013775779,0.00006835272,0.00054529385,0.0000029700439,0.00020404095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989592,0.0004748409,0.00015707918,0.00014015123,0.00015601204,0.00011273385],"domain_scores_gemma":[0.9957558,0.0013628089,0.002128467,0.00014678118,0.00027740584,0.00032875405],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021904816,0.00025082158,0.00040857578,0.0014493115,0.00038682952,0.00064859324,0.00031483243,0.00038250352,0.00097003236],"category_scores_gemma":[0.007474982,0.00017140068,0.00047491628,0.0010368066,0.00034236803,0.0004508385,0.0005724781,0.0005892911,0.0001680354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040489042,0.00002849961,0.99456364,0.000027860664,0.000031163512,0.0002489316,0.00009463502,0.00006693721,0.00012075674,0.000027895732,0.00004954911,0.004335352],"study_design_scores_gemma":[0.000020693764,0.000892938,0.9936278,0.000056981906,0.00011609972,0.0030933025,0.00031079497,0.0005684353,0.00058118044,0.00012600643,0.0005932746,0.000012554012],"about_ca_topic_score_codex":0.0014781922,"about_ca_topic_score_gemma":0.0010536205,"teacher_disagreement_score":0.0021904816,"about_ca_system_score_codex":0.0005327414,"about_ca_system_score_gemma":0.00065950403,"threshold_uncertainty_score":0.01158452},"labels":[],"label_agreement":null},{"id":"W2922749437","doi":"10.1177/1756286419835708","title":"Outcome, efficacy and safety of endovascular thrombectomy in ischaemic stroke according to time to reperfusion: data from a multicentre registry","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Modified Rankin Scale; Confounding; Logistic regression; Stroke (engine); Odds ratio; Confidence interval; Internal medicine; Clinical trial; Surgery; Ischemic stroke; Ischemia","score_opus":0.021354438755035187,"score_gpt":0.3062179837653848,"score_spread":0.2848635450103496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922749437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978517,0.00025387085,0.0001262782,0.00004608849,0.0000057628276,0.000012491053,0.001564835,0.0000054551942,0.00013343971],"genre_scores_gemma":[0.9978294,0.00010719366,0.000105804254,0.000021563192,0.000017328131,0.00002807017,0.0018485836,0.0000032088874,0.000038903912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99640673,0.0014645648,0.0007072501,0.00063276617,0.00052175566,0.00026690157],"domain_scores_gemma":[0.98473316,0.002425765,0.009912456,0.0013725854,0.00079057255,0.0007653637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034214554,0.00039349284,0.00067172584,0.0012437546,0.00029332054,0.0007810393,0.0007580962,0.00065939553,0.0008505665],"category_scores_gemma":[0.009009808,0.00033078823,0.0010603114,0.0023954508,0.00034668614,0.0007145978,0.0007301282,0.00058913155,0.00021242708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000573679,0.00003203156,0.9981273,0.000019792424,0.00023641929,0.000036957623,0.000032446434,0.000099930614,0.000082795006,0.000012597807,0.0001448877,0.0006011743],"study_design_scores_gemma":[0.000051681276,0.00010175332,0.99918383,0.0000059393715,0.00010549859,0.00014072671,0.000032481556,0.00025995617,0.000037345668,0.000016176204,0.00005919312,0.000005323338],"about_ca_topic_score_codex":0.0032705148,"about_ca_topic_score_gemma":0.0029667546,"teacher_disagreement_score":0.0034214554,"about_ca_system_score_codex":0.00042592577,"about_ca_system_score_gemma":0.00051204994,"threshold_uncertainty_score":0.0180946},"labels":[],"label_agreement":null},{"id":"W2944153925","doi":"10.1177/1756286419843458","title":"Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: A pilot study","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mirabegron; Overactive bladder; Urinary incontinence; Quality of life (healthcare); Urinary urgency; Parkinson's disease; Visual analogue scale; Refractory (planetary science); Montreal Cognitive Assessment; Urinary system; Rating scale; Urology; Physical therapy; Internal medicine; Disease; Cognitive impairment","score_opus":0.03204323492826271,"score_gpt":0.34293664964950843,"score_spread":0.3108934147212457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944153925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99881846,0.0006329587,0.000090546564,0.000041209663,0.000010298811,0.00013733582,0.000038130303,0.0000043292157,0.00022664755],"genre_scores_gemma":[0.9983758,0.00049788813,0.00047511313,0.00010081404,0.00006213574,0.00017441579,0.0001585353,0.00000224509,0.00015299908],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967015,0.00017761184,0.000028228033,0.00004155791,0.000042402142,0.000040020845],"domain_scores_gemma":[0.9992448,0.0002718758,0.00012603034,0.00005871993,0.00006335119,0.0002352321],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011932873,0.00039650733,0.0009599156,0.00020832002,0.00033602826,0.00037219728,0.0002342946,0.0004535978,0.0015856728],"category_scores_gemma":[0.0013525815,0.00017978768,0.00076401606,0.0001877396,0.0004243082,0.00038454623,0.00027491874,0.00051982835,0.00030177014],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.423715,0.08329853,0.13666503,0.0013353677,0.000936774,0.0033321865,0.0013917444,0.0012076381,0.09169996,0.00016761174,0.00076525914,0.25548494],"study_design_scores_gemma":[0.032363746,0.84740037,0.112097435,0.000039586463,0.00041723825,0.0014479858,0.00020456778,0.0008604613,0.003412031,0.000042658587,0.0016850082,0.000028955723],"about_ca_topic_score_codex":0.0003767404,"about_ca_topic_score_gemma":0.00046159857,"teacher_disagreement_score":0.0015856728,"about_ca_system_score_codex":0.00022287702,"about_ca_system_score_gemma":0.0005402811,"threshold_uncertainty_score":0.006310761},"labels":[],"label_agreement":null},{"id":"W2956892819","doi":"10.1177/1756286419860652","title":"Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Randomized controlled trial; Odds ratio; Thrombolysis; Clinical trial; Clinical equipoise; Stroke (engine); Population; Post-hoc analysis; Internal medicine; Physical therapy; Myocardial infarction","score_opus":0.018548910621985673,"score_gpt":0.3288484960183792,"score_spread":0.3102995853963935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956892819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992328,0.0017567696,0.0018014127,0.0004276988,0.00029312473,0.0025582626,0.00018393938,0.000047694662,0.00060306286],"genre_scores_gemma":[0.9947967,0.0003255541,0.0014756325,0.0004906021,0.00022576122,0.0022068822,0.00019547547,0.000008440678,0.0002749376],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9835084,0.013982044,0.00074542954,0.0007357364,0.0005634054,0.00046494626],"domain_scores_gemma":[0.99083275,0.0050892085,0.0020456135,0.0007490753,0.00036908913,0.0009141463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01276126,0.0011290669,0.0019648755,0.00037308643,0.0003283319,0.0011841366,0.00057863386,0.0014616088,0.0023487334],"category_scores_gemma":[0.012179628,0.00049163046,0.0027536782,0.00041185535,0.0010646442,0.0007367588,0.0005904461,0.0017019582,0.0003013501],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9859702,0.0029263196,0.0022893609,0.0002316633,0.0023386546,0.000024247482,0.000062167506,0.00027788887,0.0011233065,0.00008424261,0.00014507255,0.0045268736],"study_design_scores_gemma":[0.898666,0.08915874,0.008460787,0.00003310162,0.0014927762,0.000038498394,0.00002342732,0.00088883546,0.00059387286,0.00027073768,0.00035433032,0.000018918903],"about_ca_topic_score_codex":0.00027359359,"about_ca_topic_score_gemma":0.00042418952,"teacher_disagreement_score":0.01276126,"about_ca_system_score_codex":0.0005276577,"about_ca_system_score_gemma":0.0013432021,"threshold_uncertainty_score":0.06748885},"labels":[],"label_agreement":null},{"id":"W3025164808","doi":"10.1177/1756286420915005","title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Biogen","keywords":"Dimethyl fumarate; Medicine; Multiple sclerosis; Adverse effect; Expanded Disability Status Scale; Cohort; Placebo; Incidence (geometry); Internal medicine; Population; Relapsing remitting; Magnetic resonance imaging; Gastroenterology; Pathology; Radiology; Immunology","score_opus":0.031607016600169534,"score_gpt":0.272147108999602,"score_spread":0.24054009239943244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025164808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972996,0.00087832264,0.00019708356,0.00007105253,0.000013409504,0.000088920504,0.0007273573,0.000028843768,0.00069535134],"genre_scores_gemma":[0.99772614,0.00020097978,0.00021379009,0.0001025337,0.000024015859,0.00006126667,0.0012897288,0.0000046396685,0.00037694274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991679,0.00023335085,0.00011280258,0.00014056085,0.00022524624,0.00012014117],"domain_scores_gemma":[0.9969805,0.00042069415,0.0014143661,0.0003339407,0.00044036767,0.00041024492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030501322,0.00049621897,0.0012865406,0.00040912651,0.00058779813,0.0006674296,0.00034402817,0.00049773086,0.0009893497],"category_scores_gemma":[0.0022010943,0.00024919593,0.0008907379,0.00034494657,0.00026792436,0.00070854457,0.000420122,0.000889888,0.00039949693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04695043,0.0021482327,0.8626403,0.00034607126,0.0014954207,0.00048629017,0.0005474157,0.00044855836,0.01059724,0.000052424162,0.001507915,0.07277977],"study_design_scores_gemma":[0.0019010879,0.022553474,0.96894026,0.0000350004,0.0006403689,0.0008043002,0.000107974796,0.00039439794,0.0023541013,0.000046261597,0.0021877831,0.000035035366],"about_ca_topic_score_codex":0.00059639243,"about_ca_topic_score_gemma":0.0011260883,"teacher_disagreement_score":0.0030501322,"about_ca_system_score_codex":0.00040328578,"about_ca_system_score_gemma":0.00027205137,"threshold_uncertainty_score":0.016130865},"labels":[],"label_agreement":null},{"id":"W3034546965","doi":"10.1177/1756286420932036","title":"Neurological manifestations and implications of COVID-19 pandemic","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Long-Term Effects of COVID-19","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Pandemic; Comorbidity; Neurology; Intensive care medicine; Stroke (engine); Coronavirus; Disease; Hyposmia; Pediatrics; Encephalopathy; Coronavirus disease 2019 (COVID-19); Internal medicine; Psychiatry; Infectious disease (medical specialty)","score_opus":0.06617230146732682,"score_gpt":0.4122730557635806,"score_spread":0.34610075429625375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034546965","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051896553,0.9853639,0.00018411476,0.0048134397,0.000800096,0.000019250223,0.00015750347,0.000011956702,0.0034599681],"genre_scores_gemma":[0.043014448,0.95068926,0.00032505192,0.003274808,0.0016527757,0.000023721688,0.0001973977,0.0000047478366,0.00081777875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99942493,0.00020031325,0.00015007291,0.00006419913,0.0001139919,0.000046473044],"domain_scores_gemma":[0.9989405,0.00039872024,0.00036122388,0.000021102469,0.0002318149,0.000046614892],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006517212,0.00034180624,0.0004554368,0.001449357,0.00029986896,0.0010799622,0.00037167536,0.0007711007,0.0018398952],"category_scores_gemma":[0.003343781,0.00011893986,0.00055087433,0.0010491257,0.00052714394,0.0010705598,0.0005524808,0.00076442055,0.00025599278],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004527905,0.00004979872,0.019209659,0.08020027,0.0011093876,0.021461338,0.0026990278,0.000983806,0.0028745965,0.010022024,0.12069122,0.74024606],"study_design_scores_gemma":[0.00006295623,0.00031427242,0.050945748,0.07774428,0.0014257196,0.08897346,0.0033368636,0.00039976064,0.0013328933,0.008714136,0.7665973,0.00015269191],"about_ca_topic_score_codex":0.0035924963,"about_ca_topic_score_gemma":0.0052094273,"teacher_disagreement_score":0.0035924963,"about_ca_system_score_codex":0.0008561829,"about_ca_system_score_gemma":0.0019014739,"threshold_uncertainty_score":0.00714314},"labels":[],"label_agreement":null},{"id":"W3037795043","doi":"10.1177/1756286420935019","title":"Expert opinion on the use of cladribine tablets in clinical practice","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Expert opinion; Cladribine; Clinical Practice; Alternative medicine; Intensive care medicine; Traditional medicine; Medical physics; Family medicine; Internal medicine; Pathology","score_opus":0.3616787011441253,"score_gpt":0.5036940022402069,"score_spread":0.14201530109608157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037795043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00037428705,0.9653949,0.0009847317,0.023582138,0.004202906,0.00019945133,0.00021722479,0.00002012319,0.005024196],"genre_scores_gemma":[0.0080856765,0.97469634,0.0039271154,0.009797399,0.0016608263,0.0002934244,0.0003184293,0.000009592641,0.0012112194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97712153,0.011321864,0.0056019425,0.00088670093,0.0045875832,0.0004803722],"domain_scores_gemma":[0.9402494,0.03810137,0.0064411312,0.0007922424,0.013474088,0.00094173755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024354272,0.00088210276,0.0024207712,0.0026283644,0.0004142565,0.0021580267,0.0028896772,0.004481678,0.005446887],"category_scores_gemma":[0.05793379,0.00050454465,0.0017479481,0.0027728411,0.0009805612,0.0022686168,0.0015493946,0.0026495846,0.001885226],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018241868,0.00004181696,0.00039391348,0.19689198,0.000569707,0.00030253376,0.0005597014,0.00029862416,0.0006492,0.002984169,0.10792582,0.68920004],"study_design_scores_gemma":[0.00015466542,0.000118457705,0.0015347779,0.29566258,0.0014553916,0.00064113585,0.00046272192,0.00020335411,0.00042331617,0.0029588582,0.69633454,0.00005016455],"about_ca_topic_score_codex":0.0026026207,"about_ca_topic_score_gemma":0.0037370992,"teacher_disagreement_score":0.024354272,"about_ca_system_score_codex":0.0023578473,"about_ca_system_score_gemma":0.008742293,"threshold_uncertainty_score":0.1287992},"labels":[],"label_agreement":null},{"id":"W3046496809","doi":"10.1177/1756286420936165","title":"Multiple sclerosis and nutrition: back to the future?","year":2020,"lang":"en","type":"editorial","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Deutschen Multiple Sklerose Gesellschaft; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Multiple sclerosis; Clinical neurology; Physical medicine and rehabilitation; Intensive care medicine; Neuroscience; Immunology","score_opus":0.03862480676914403,"score_gpt":0.31613213964389814,"score_spread":0.2775073328747541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046496809","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025534273,0.0042908313,0.00005762733,0.030560935,0.9643965,0.0000072988832,0.000020717704,0.000035721412,0.00060498045],"genre_scores_gemma":[0.0002981604,0.0049411757,0.000078341094,0.022431957,0.96799546,0.000012330668,0.000017368344,0.00001894073,0.004206346],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99552995,0.0010756798,0.00061375403,0.00039847268,0.0020748265,0.00030726826],"domain_scores_gemma":[0.97433734,0.012050819,0.0010933354,0.00053814834,0.008102251,0.0038780859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008451766,0.003869514,0.003484694,0.0032249556,0.00301996,0.008071442,0.003416347,0.015303056,0.0124497],"category_scores_gemma":[0.02703508,0.0010954154,0.0022900074,0.0013370725,0.0024736112,0.00556601,0.0015115193,0.019225985,0.011038956],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006613731,0.0000182699,0.00004053397,0.00030373444,0.000022449314,0.00013828703,0.000016849252,0.000023123994,0.00004642512,0.00042425212,0.9921119,0.006787924],"study_design_scores_gemma":[0.00012812717,0.00006614639,0.00039252292,0.0009530101,0.000082027975,0.00050116616,0.00012296104,0.00023120543,0.00010923414,0.0030512062,0.9943228,0.000039532788],"about_ca_topic_score_codex":0.0021320262,"about_ca_topic_score_gemma":0.0062967334,"teacher_disagreement_score":0.015303056,"about_ca_system_score_codex":0.0028783178,"about_ca_system_score_gemma":0.004208392,"threshold_uncertainty_score":0.044697702},"labels":[],"label_agreement":null},{"id":"W3089064542","doi":"10.1177/1756286420954083","title":"Standardized algorithm for muscle selection and dosing of botulinum toxin for Parkinson tremor using kinematic analysis","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"Merz Pharmaceuticals","keywords":"Medicine; Dosing; Botulinum toxin; Rating scale; Physical medicine and rehabilitation; Essential tremor; Quality of life (healthcare); Grip strength; Weakness; Physical therapy; Anesthesia; Internal medicine; Psychology; Surgery","score_opus":0.03389466039749872,"score_gpt":0.3268518546039901,"score_spread":0.29295719420649136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089064542","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0713187,0.00064301264,0.9093623,0.0004111648,0.00015433243,0.005592777,0.0019665866,0.0072878124,0.0032633161],"genre_scores_gemma":[0.2043073,0.00029501886,0.7848014,0.0002720188,0.00007963372,0.005641545,0.0027439108,0.00044452798,0.0014146774],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99528486,0.0016934423,0.00076091685,0.0008547362,0.0012660299,0.00014005772],"domain_scores_gemma":[0.9938006,0.0017013802,0.0012552168,0.0006195593,0.0024577696,0.000165546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060702767,0.001367981,0.0012036619,0.0021674703,0.00038393014,0.0012969034,0.0009723971,0.0006127794,0.002925217],"category_scores_gemma":[0.017279776,0.0004142079,0.0007207313,0.0009980995,0.00037758338,0.0004701855,0.0009797688,0.0008911084,0.0015201074],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005838855,0.0010151331,0.06530083,0.00050506723,0.00047712369,0.0003168161,0.00034485533,0.029389227,0.04861235,0.0016634526,0.014325962,0.83221036],"study_design_scores_gemma":[0.0038634192,0.006011795,0.15250632,0.00038194054,0.00081626937,0.00273953,0.0002680916,0.6997505,0.08267501,0.007273318,0.043287337,0.00042652735],"about_ca_topic_score_codex":0.0023089787,"about_ca_topic_score_gemma":0.002896033,"teacher_disagreement_score":0.0060702767,"about_ca_system_score_codex":0.00086440146,"about_ca_system_score_gemma":0.0021824173,"threshold_uncertainty_score":0.03210306},"labels":[],"label_agreement":null},{"id":"W3111513828","doi":"10.1177/1756286420978004","title":"COVID-19 and cerebrovascular diseases: a comprehensive overview","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Long-Term Effects of COVID-19","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Stroke (engine); Intracerebral hemorrhage; Disease; Intensive care medicine; Coagulopathy; Internal medicine; Subarachnoid hemorrhage","score_opus":0.05047681182604093,"score_gpt":0.38743677680631444,"score_spread":0.33695996498027353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111513828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021760198,0.9991443,0.000035505174,0.00026747357,0.00007787259,0.000005289839,0.000032358916,0.0000024102635,0.00021721881],"genre_scores_gemma":[0.0016058506,0.99770904,0.00013588407,0.00022860576,0.00017926948,0.000010184347,0.000055467026,8.3093335e-7,0.00007485961],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999566,0.000095137315,0.00015726937,0.0000703334,0.00007673313,0.00003449232],"domain_scores_gemma":[0.99805474,0.0012905744,0.0003506352,0.00003010085,0.00020394572,0.00007002369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093161874,0.0006572652,0.0012366034,0.005241981,0.00032642833,0.0013217233,0.00061296864,0.0010079454,0.0025521226],"category_scores_gemma":[0.002372221,0.00032521377,0.0012420145,0.0039781076,0.0003665366,0.0014147399,0.000819968,0.0009551684,0.00035698526],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031065283,0.00009207794,0.004025453,0.2590833,0.0015028295,0.00085748284,0.0005545512,0.00042432532,0.0010119291,0.0036369532,0.029392403,0.69910806],"study_design_scores_gemma":[0.000051980733,0.00040581994,0.01956676,0.22838454,0.0051981774,0.0074856393,0.00065216137,0.00028639246,0.00038199246,0.0034805383,0.7340183,0.000087688255],"about_ca_topic_score_codex":0.0028626334,"about_ca_topic_score_gemma":0.0043032127,"teacher_disagreement_score":0.005241981,"about_ca_system_score_codex":0.00075277477,"about_ca_system_score_gemma":0.0028103562,"threshold_uncertainty_score":0.00853771},"labels":[],"label_agreement":null},{"id":"W3125508314","doi":"10.1177/1756286420986727","title":"Real-world comparative safety and efficacy of tenecteplase <i>versus</i> alteplase in acute ischemic stroke patients with large vessel occlusion","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Tenecteplase; Medicine; Thrombolysis; Modified Rankin Scale; Stroke (engine); Fibrinolytic agent; Occlusion; Tissue plasminogen activator; Internal medicine; Anesthesia; Ischemia; Ischemic stroke; Myocardial infarction","score_opus":0.011863109917511558,"score_gpt":0.2901336311178049,"score_spread":0.27827052120029333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125508314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99955016,0.00012690466,0.00005123546,0.000011453216,0.0000034766456,0.000026524818,0.0000673812,0.0000022926754,0.00016063993],"genre_scores_gemma":[0.9996284,0.000054020707,0.000074424475,0.000022375176,0.00001570381,0.000024280589,0.0001566469,8.30615e-7,0.000023225379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987447,0.00072198454,0.00014982412,0.00019457717,0.000106863285,0.00008202148],"domain_scores_gemma":[0.99523735,0.0016989098,0.0020569616,0.00024991547,0.00028596388,0.00047083397],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019256859,0.00021345116,0.00043105154,0.00024164992,0.00020179938,0.00054385106,0.00018151119,0.00034587883,0.000945984],"category_scores_gemma":[0.004229832,0.00010273939,0.0004156263,0.00024015488,0.00045617105,0.00042202685,0.00020607853,0.00036018566,0.00019668648],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.346964,0.007563904,0.56752044,0.0004712253,0.0018524657,0.0005533451,0.00049415365,0.00165214,0.009646452,0.00016674209,0.00077299477,0.062342107],"study_design_scores_gemma":[0.01605382,0.17581055,0.7980743,0.000053080264,0.0011402025,0.0010369124,0.0002407708,0.0025088245,0.003891204,0.00013402612,0.0009931242,0.000063095904],"about_ca_topic_score_codex":0.00041334625,"about_ca_topic_score_gemma":0.00041145665,"teacher_disagreement_score":0.0019256859,"about_ca_system_score_codex":0.00048144592,"about_ca_system_score_gemma":0.0002862454,"threshold_uncertainty_score":0.010184169},"labels":[],"label_agreement":null},{"id":"W3135190823","doi":"10.1177/1756286420987941","title":"Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"AbbVie Biotherapeutics; Biogen","keywords":"Medicine; Daclizumab; Multiple sclerosis; BETA (programming language); Relapsing remitting; Internal medicine; Oncology; Immunology; Monoclonal antibody; Antibody","score_opus":0.06762489834413932,"score_gpt":0.341432496039235,"score_spread":0.27380759769509566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135190823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910425,0.00260173,0.0004482896,0.00019525511,0.00006818509,0.0024597626,0.0015633152,0.000060870418,0.0015600304],"genre_scores_gemma":[0.98992926,0.0007629991,0.002003819,0.0006309783,0.00015139164,0.002722505,0.0024004884,0.000016457047,0.0013820688],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9984113,0.00086132094,0.00016864255,0.00019282612,0.00022880835,0.00013713563],"domain_scores_gemma":[0.99576664,0.0011458289,0.0014265361,0.00045718712,0.00044511582,0.0007586175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008001976,0.00065396045,0.0014661339,0.00027060581,0.0004908653,0.0010488074,0.00048460142,0.00123102,0.0028272416],"category_scores_gemma":[0.004368751,0.0002983988,0.001339942,0.00029856243,0.0005321603,0.0007965117,0.00052051677,0.0013402343,0.0006633578],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8585411,0.015563456,0.036587596,0.0011501318,0.0016525902,0.0002885624,0.0003464714,0.0007364631,0.012761626,0.00019921659,0.0025973169,0.06957552],"study_design_scores_gemma":[0.5042751,0.32584298,0.15326156,0.00029567294,0.0016241027,0.00046818584,0.00013698089,0.0011507374,0.005286284,0.0003137878,0.007270093,0.00007456412],"about_ca_topic_score_codex":0.00023894757,"about_ca_topic_score_gemma":0.00094150077,"teacher_disagreement_score":0.008001976,"about_ca_system_score_codex":0.00050226395,"about_ca_system_score_gemma":0.0010057401,"threshold_uncertainty_score":0.04231894},"labels":[],"label_agreement":null},{"id":"W3138369521","doi":"10.1177/1756286421998905","title":"Expanding indications for endovascular thrombectomy-how to leave no patient behind","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Thrombolysis; Stroke (engine); Occlusion; Endovascular treatment; Standard of care; Radiology; Intensive care medicine; Surgery; Myocardial infarction; Cardiology","score_opus":0.041407256598224786,"score_gpt":0.35767947750906637,"score_spread":0.31627222091084156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138369521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009418123,0.9969613,0.00011211519,0.0014506964,0.00029715718,0.000005845434,0.000022154723,0.0000065007976,0.001050058],"genre_scores_gemma":[0.00049924204,0.9980405,0.00024656428,0.0007056519,0.00023502122,0.00000569669,0.000030329267,0.00000185179,0.00023516988],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996427,0.00008477232,0.00010162468,0.00005258771,0.00009310994,0.0000251426],"domain_scores_gemma":[0.99925786,0.00046664692,0.00009853957,0.000013999867,0.00012729854,0.00003564574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076603325,0.00067135267,0.0011022887,0.0022768874,0.0003047861,0.0012026466,0.00070423546,0.0012100062,0.0050738323],"category_scores_gemma":[0.0017618438,0.00021556947,0.0007192163,0.0015127186,0.0004928659,0.0020874417,0.00062947714,0.0017775341,0.0017518605],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056149005,0.000041406925,0.00026535956,0.03316364,0.00009885009,0.00027646258,0.000116387615,0.00016164906,0.0004984755,0.0037452115,0.037523095,0.9240534],"study_design_scores_gemma":[0.000038186416,0.00007206467,0.0015177793,0.053446602,0.0003245406,0.0028177665,0.00022806293,0.00009764216,0.00018897257,0.0047891703,0.9364508,0.000028457414],"about_ca_topic_score_codex":0.0012242519,"about_ca_topic_score_gemma":0.0027630527,"teacher_disagreement_score":0.0050738323,"about_ca_system_score_codex":0.000532468,"about_ca_system_score_gemma":0.0016088684,"threshold_uncertainty_score":0.016973674},"labels":[],"label_agreement":null},{"id":"W3157239883","doi":"10.1177/1756286420982134","title":"Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"NIHR Cambridge Biomedical Research Centre; Bayer HealthCare; National Institute for Health and Care Research; Sanofi","keywords":"Alemtuzumab; Medicine; Multiple sclerosis; Internal medicine; Clinical trial; Randomized controlled trial; Immunology; Transplantation","score_opus":0.04590724287686678,"score_gpt":0.3464066050044256,"score_spread":0.30049936212755884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157239883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98674715,0.007840643,0.00033176137,0.0006925019,0.00015298172,0.0005665109,0.0017082107,0.000054781853,0.0019054568],"genre_scores_gemma":[0.98783535,0.0019168193,0.0010211776,0.0010653257,0.0004414263,0.0010003601,0.0047367546,0.000021431038,0.0019612904],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99792093,0.0012082697,0.00010633575,0.00026211544,0.00022528181,0.0002770662],"domain_scores_gemma":[0.99662566,0.00053625397,0.001071406,0.0004136614,0.0004607066,0.0008923556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006598852,0.0012114858,0.0021983436,0.00033590526,0.0006507352,0.0011661969,0.00083117886,0.0018114978,0.0017431654],"category_scores_gemma":[0.0053659496,0.0003279258,0.0018959687,0.0004809549,0.00070359715,0.0009421387,0.00066666957,0.0022901914,0.00039441674],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91179395,0.0053553306,0.0218057,0.00037032712,0.004001849,0.00018266517,0.00015749982,0.0018049068,0.0042597568,0.00021823436,0.0066550197,0.043394838],"study_design_scores_gemma":[0.69552183,0.15667999,0.12561184,0.00019330237,0.006865869,0.0005387468,0.00008176769,0.0021682747,0.0026667845,0.00070265034,0.00886394,0.00010499771],"about_ca_topic_score_codex":0.0011193933,"about_ca_topic_score_gemma":0.0016320655,"teacher_disagreement_score":0.006598852,"about_ca_system_score_codex":0.0009024067,"about_ca_system_score_gemma":0.0011959659,"threshold_uncertainty_score":0.03489846},"labels":[],"label_agreement":null},{"id":"W3162974988","doi":"10.1177/17562864211014389","title":"A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Neuromyelitis optica; Medicine; Disease; Subclinical infection; Spectrum disorder; Magnetic resonance imaging; Multiple sclerosis; Intensive care medicine; Pediatrics; Pathology; Immunology; Radiology; Psychiatry","score_opus":0.06666058728059476,"score_gpt":0.4407415941948044,"score_spread":0.37408100691420965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162974988","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000038377355,0.99886984,0.000049091563,0.00048670298,0.00016575358,0.0000018365419,0.000005969493,0.000003418746,0.0003789924],"genre_scores_gemma":[0.00043673714,0.9984738,0.00018284771,0.00039889704,0.00027369751,0.0000037064867,0.000012191096,0.0000014375784,0.00021672636],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996126,0.00011346229,0.000079896345,0.00004926366,0.000119772194,0.000025128276],"domain_scores_gemma":[0.99911517,0.00047778158,0.000108311,0.000023448903,0.00023109406,0.000044220433],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010504839,0.0007156869,0.0014572748,0.003167305,0.000228381,0.0012633945,0.000814844,0.0013197773,0.0024830396],"category_scores_gemma":[0.001921341,0.00025084143,0.0005711698,0.0022027923,0.00071005156,0.0020374293,0.00053936907,0.002170771,0.0017405279],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000080004516,0.00003474066,0.0003294512,0.02081914,0.00011417159,0.00030490648,0.00009339374,0.00016581432,0.0008142678,0.003131088,0.038814355,0.9352987],"study_design_scores_gemma":[0.000027558845,0.000083658,0.0018061341,0.022364208,0.00023457792,0.0048161102,0.00015952262,0.00011215687,0.00033831864,0.0028868576,0.9671387,0.000032190008],"about_ca_topic_score_codex":0.0016947356,"about_ca_topic_score_gemma":0.0025714391,"teacher_disagreement_score":0.003167305,"about_ca_system_score_codex":0.00076236326,"about_ca_system_score_gemma":0.0012972474,"threshold_uncertainty_score":0.0083066225},"labels":[],"label_agreement":null},{"id":"W3164111830","doi":"10.1177/17562864211018561","title":"Cannabis and its derivatives for the use of motor symptoms in Parkinson’s disease: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Meta-analysis; Parkinson's disease; Motor symptoms; Disease; Cannabis; Systematic review; Psychiatry; Neuroscience; MEDLINE; Physical medicine and rehabilitation; Intensive care medicine; Internal medicine; Psychology","score_opus":0.11506435694121224,"score_gpt":0.3927733063084333,"score_spread":0.27770894936722107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164111830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004860865,0.9938632,0.00027310275,0.00013482549,0.000085891006,0.00021492678,0.00037948467,0.000015770733,0.00017190748],"genre_scores_gemma":[0.14293437,0.8527236,0.0015918798,0.00058758346,0.00023082475,0.00090912066,0.0007463051,0.000020497706,0.00025586082],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9930801,0.0029774758,0.0021318782,0.00070113403,0.000858368,0.00025098684],"domain_scores_gemma":[0.98288536,0.012160497,0.0029819373,0.0004684354,0.0012515709,0.00025218818],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009451416,0.0024124943,0.015897235,0.006504581,0.00070525974,0.0027084409,0.0019732616,0.0019370348,0.0037126285],"category_scores_gemma":[0.024167811,0.0011569369,0.032769512,0.006675008,0.0006515076,0.0014146415,0.001347472,0.001373991,0.00024969561],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021572781,0.00004235754,0.00450823,0.46369642,0.5143263,0.00015836862,0.00007585056,0.00046346313,0.00025420365,0.00011236123,0.0006264736,0.013578658],"study_design_scores_gemma":[0.0005677723,0.00021665626,0.0042569363,0.030655438,0.9623128,0.0001347481,0.000046943132,0.00018296018,0.0001083937,0.0001402875,0.0013529928,0.000024055245],"about_ca_topic_score_codex":0.006390386,"about_ca_topic_score_gemma":0.014075719,"teacher_disagreement_score":0.015897235,"about_ca_system_score_codex":0.0023962623,"about_ca_system_score_gemma":0.0039199293,"threshold_uncertainty_score":0.049984455},"labels":[],"label_agreement":null},{"id":"W3173363521","doi":"10.1177/17562864211021177","title":"A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Biogen","keywords":"Fingolimod; Medicine; Dimethyl fumarate; Propensity score matching; Internal medicine; Hazard ratio; Confidence interval; Multiple sclerosis; Relapsing remitting; Gastroenterology; Disease; Immunology","score_opus":0.08033330319553018,"score_gpt":0.33582630447555095,"score_spread":0.2554930012800208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173363521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972204,0.0007238421,0.00080569304,0.000050115937,0.000072206254,0.000159201,0.0005649241,0.000007871546,0.0003956871],"genre_scores_gemma":[0.9987411,0.00012526313,0.00028340722,0.00004532548,0.000026657013,0.00010974798,0.0005013333,0.0000026088533,0.00016455684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99710745,0.001217539,0.000411223,0.00072910875,0.0002962454,0.00023841563],"domain_scores_gemma":[0.9972017,0.0008110156,0.001090881,0.000456457,0.00020526446,0.00023464505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037282438,0.00046646062,0.0011162477,0.0006878836,0.00047917865,0.00078402803,0.00066216843,0.00094238075,0.0026720122],"category_scores_gemma":[0.008424294,0.00041763452,0.002507572,0.0008889921,0.0003686824,0.0005730622,0.0005906316,0.0006936841,0.0003026746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21766189,0.0021257298,0.7296032,0.00057628955,0.02004581,0.00040115544,0.00040929537,0.0022170846,0.0033015555,0.0008772725,0.0013519817,0.021428833],"study_design_scores_gemma":[0.016539909,0.03445842,0.9159861,0.0001289806,0.011114963,0.0006792384,0.0005101746,0.013538925,0.0012386406,0.0016553897,0.004047056,0.00010220218],"about_ca_topic_score_codex":0.0018166051,"about_ca_topic_score_gemma":0.0011291465,"teacher_disagreement_score":0.0037282438,"about_ca_system_score_codex":0.00048294454,"about_ca_system_score_gemma":0.00059712614,"threshold_uncertainty_score":0.019717038},"labels":[],"label_agreement":null},{"id":"W4226062860","doi":"10.1177/17562864211058298","title":"Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"EMD Serono; MedDay Pharmaceuticals; Genentech; Serono Symposia International Foundation; Servier; Aristotle University of Thessaloniki; Pirogov Russian National Research Medical University; Medizinische Universität Wien; Rigshospitalet; Università degli Studi di Genova; Hebrew University of Jerusalem; Universität Wien; Queen Mary University of London; CSL Behring; Gentofte Hospital; Fresenius Medical Care North America; Five Prime Therapeutics; Ironwood Pharmaceuticals, Incorporated; Vertex Pharmaceuticals; Ottawa Hospital Research Institute; Bayer Vital; Bristol-Myers Squibb; Bundesministerium für Bildung und Forschung; Atara Biotherapeutics; Merck KGaA; Univerzita Karlova v Praze; Pfizer; Biogen; Celgene; Teva Pharmaceutical Industries; Sanofi; GW Pharmaceuticals; Università degli Studi di Napoli Federico II; Bayer HealthCare; Deutsche Forschungsgemeinschaft; Directorate for Biological Sciences; GlaxoSmithKline","keywords":"Cladribine; Medicine; Expert opinion; Vaccination; Coronavirus disease 2019 (COVID-19); Clinical Practice; Dosing; MEDLINE; Multiple sclerosis; Family medicine; Intensive care medicine; Pharmacology; Internal medicine; Pathology; Immunology; Disease; Infectious disease (medical specialty)","score_opus":0.31871533135323626,"score_gpt":0.5275843612080184,"score_spread":0.20886902985478217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226062860","genre_codex":"commentary","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0072204503,0.12365803,0.016172986,0.77267396,0.04206736,0.0020732332,0.001208445,0.00018391499,0.03474165],"genre_scores_gemma":[0.21687855,0.2517527,0.13382262,0.3353083,0.037544098,0.005425471,0.0035941557,0.00025257492,0.015421471],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.82500863,0.09556503,0.044173982,0.0055484087,0.026029242,0.0036746087],"domain_scores_gemma":[0.5991156,0.17462265,0.034002077,0.0064240233,0.1722912,0.013544383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13157922,0.0010594154,0.0023148837,0.004180183,0.0016984927,0.004742271,0.0054170643,0.01505625,0.0060468223],"category_scores_gemma":[0.30064222,0.0010090225,0.0034736537,0.0033399167,0.0028068586,0.004158759,0.0051529775,0.009009349,0.0032168191],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004695799,0.00015249288,0.004641457,0.033173997,0.00089353096,0.0013274511,0.0063609127,0.0014347578,0.0018260113,0.006751625,0.5708927,0.37207553],"study_design_scores_gemma":[0.00037408026,0.0002744531,0.0035175069,0.085756294,0.00095976645,0.0013103954,0.0046525127,0.0014986082,0.0009807644,0.015126639,0.8853227,0.00022641117],"about_ca_topic_score_codex":0.0035533262,"about_ca_topic_score_gemma":0.0034918017,"teacher_disagreement_score":0.13157922,"about_ca_system_score_codex":0.0053872573,"about_ca_system_score_gemma":0.02824574,"threshold_uncertainty_score":0.69586575},"labels":[],"label_agreement":null},{"id":"W4285250308","doi":"10.1177/17562864221099472","title":"Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Fondaparinux; Low molecular weight heparin; Internal medicine; Cochrane Library; Thrombosis; Randomized controlled trial; Meta-analysis; Dosing; Cohort study; Observational study; Venous thromboembolism","score_opus":0.024988881798681674,"score_gpt":0.3877964226678904,"score_spread":0.3628075408692087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285250308","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014155684,0.9846748,0.00014538565,0.00015699127,0.0001090267,0.00021223686,0.0002650854,0.000006568571,0.00027422985],"genre_scores_gemma":[0.39935884,0.5966638,0.0013280143,0.0007617709,0.00027877657,0.0007560659,0.0005934647,0.000013830566,0.00024542585],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9934378,0.003010179,0.0022013015,0.00056770316,0.0006234405,0.00015953157],"domain_scores_gemma":[0.98471767,0.0109223835,0.0031669773,0.0002500069,0.000731242,0.00021171744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008096433,0.0011695075,0.008397521,0.0037711742,0.00039255936,0.0019307744,0.0011265128,0.001551853,0.0021046565],"category_scores_gemma":[0.021256963,0.00080079446,0.018319463,0.0034201122,0.0005511837,0.00095952104,0.00087380933,0.0012898399,0.00012669088],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0102432845,0.00011776884,0.00994042,0.47077945,0.48355758,0.00012641959,0.00012043558,0.00041656784,0.00037292414,0.00018600216,0.0004121189,0.023727],"study_design_scores_gemma":[0.0027915363,0.0013562113,0.014198165,0.04329531,0.93537503,0.0001659215,0.00009910819,0.0002493215,0.00026909562,0.0002951829,0.0018703538,0.00003480827],"about_ca_topic_score_codex":0.0041674473,"about_ca_topic_score_gemma":0.007614888,"teacher_disagreement_score":0.008397521,"about_ca_system_score_codex":0.0016528008,"about_ca_system_score_gemma":0.0021426587,"threshold_uncertainty_score":0.042818487},"labels":[],"label_agreement":null},{"id":"W4310782882","doi":"10.1177/17562864221139632","title":"Endovascular treatment for anterior circulation large-vessel occlusion ischemic stroke with low ASPECTS: a systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Modified Rankin Scale; Stroke (engine); MEDLINE; Systematic review; Ischemic stroke; Randomized controlled trial; Internal medicine; Clinical trial; Ischemia","score_opus":0.04180377092369003,"score_gpt":0.3360274067380769,"score_spread":0.2942236358143869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310782882","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045823907,0.9938846,0.00044899294,0.00015290346,0.000116354655,0.00020903909,0.0003910869,0.000019007277,0.00019561818],"genre_scores_gemma":[0.14997245,0.8446669,0.0021196457,0.00072299526,0.0003197918,0.0010269902,0.00088357413,0.00002568853,0.00026210275],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9925687,0.0035423369,0.0021234974,0.0007491,0.0007410678,0.00027520617],"domain_scores_gemma":[0.9860454,0.009743209,0.002430805,0.00046138628,0.0011111501,0.00020797914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010899356,0.00277895,0.019668795,0.0070611034,0.000610158,0.0030492523,0.0021051813,0.002268563,0.003260061],"category_scores_gemma":[0.022825502,0.0014134895,0.039000574,0.007495451,0.0006343606,0.0015527545,0.0013259838,0.0016259584,0.00030997538],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016098995,0.000031278407,0.003053015,0.3278226,0.6580018,0.000113220296,0.00006179279,0.00045119732,0.00016894813,0.00008941374,0.0004342573,0.008162543],"study_design_scores_gemma":[0.00035082296,0.00013685653,0.002504683,0.016967949,0.97878724,0.000067815796,0.000029096644,0.00012769272,0.00006338362,0.000099909375,0.00084916526,0.00001542043],"about_ca_topic_score_codex":0.0055437568,"about_ca_topic_score_gemma":0.011973163,"teacher_disagreement_score":0.019668795,"about_ca_system_score_codex":0.0020130754,"about_ca_system_score_gemma":0.0029783698,"threshold_uncertainty_score":0.057641983},"labels":[],"label_agreement":null},{"id":"W4318815070","doi":"10.1177/17562864221150329","title":"Plasma extracellular vesicle tau, β-amyloid, and α-synuclein and the progression of Parkinson’s disease: a follow-up study","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare; Taipei Medical University; Parkinsonfonden; National Taiwan University; National Taiwan University Hospital; Ministry of Science and Technology, Taiwan","keywords":"Medicine; Parkinson's disease; Internal medicine; Biomarker; Disease; Cohort; Alpha-synuclein; Oncology; Endocrinology; Biology","score_opus":0.01881479634039804,"score_gpt":0.29505705972939855,"score_spread":0.2762422633890005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318815070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99921966,0.00021172689,0.000082704326,0.000011944051,0.0000066695193,0.000024652021,0.00024202857,0.000003698863,0.00019692723],"genre_scores_gemma":[0.99873227,0.00010721413,0.00011846931,0.000020429225,0.000013515892,0.000030839794,0.00066392135,0.0000025867637,0.0003106853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996271,0.000063645435,0.000029165025,0.00013697632,0.00007378804,0.000069311114],"domain_scores_gemma":[0.9989635,0.00010768959,0.00025920427,0.00015474812,0.00025414306,0.0002606626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008766789,0.0005560224,0.0006346218,0.000760163,0.0010189426,0.0006577213,0.00046079035,0.0008357168,0.00095988315],"category_scores_gemma":[0.0016580138,0.00047288847,0.0007235535,0.00076165784,0.0002464085,0.000682836,0.00051446696,0.0009013067,0.00035827555],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014564486,0.0004265741,0.9939063,0.000016111631,0.00020631308,0.0004346419,0.0002050573,0.000048378315,0.00076164847,0.000011690248,0.00012341671,0.0024033235],"study_design_scores_gemma":[0.00004120598,0.00070512475,0.99835974,0.000004804233,0.00010353553,0.00031711374,0.000077026605,0.000105796906,0.00009848997,0.000014849412,0.00016783806,0.000004498266],"about_ca_topic_score_codex":0.006176249,"about_ca_topic_score_gemma":0.0047392966,"teacher_disagreement_score":0.006176249,"about_ca_system_score_codex":0.0004546166,"about_ca_system_score_gemma":0.00040783623,"threshold_uncertainty_score":0.012280643},"labels":[],"label_agreement":null},{"id":"W4380785062","doi":"10.1177/17562864231180715","title":"Arterial stiffness and its influence on cerebral morphology and cognitive function","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Cardiovascular Health and Disease Prevention","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alzheimer Society","keywords":"Arterial stiffness; Medicine; Pulse wave velocity; Cardiology; Hyperintensity; Internal medicine; Blood pressure; Dementia; Ambulatory blood pressure; Pulse pressure; Magnetic resonance imaging; Disease; Radiology","score_opus":0.017981206129568533,"score_gpt":0.3056240441426175,"score_spread":0.28764283801304896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380785062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985948,0.0008314867,0.000094562536,0.000027005943,0.000005615405,0.000003109656,0.00009820464,0.0000037412653,0.00034153677],"genre_scores_gemma":[0.9994779,0.00021543904,0.00010524923,0.000008360586,0.000015688784,0.0000027801898,0.00007101526,0.0000015468894,0.00010201991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999821,0.00006666355,0.000011502748,0.00003440406,0.00003396053,0.000032478347],"domain_scores_gemma":[0.99852836,0.0004983175,0.00057903165,0.000092318114,0.000120143886,0.0001818898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003807886,0.00026853583,0.00020438468,0.00054222293,0.00014290855,0.00035144214,0.00013752436,0.0002448733,0.0013790341],"category_scores_gemma":[0.0020310576,0.00012506926,0.00020544328,0.00040132873,0.00020637643,0.00013796765,0.00018026248,0.00034199728,0.00017587867],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001821868,0.00018086152,0.9779675,0.00005909915,0.00027139555,0.00037720904,0.00012610585,0.00017444945,0.005573815,0.000053775097,0.0001226047,0.013271321],"study_design_scores_gemma":[0.0000036531608,0.00012786519,0.99925524,0.0000034450616,0.00002244565,0.00023846184,0.000012202977,0.00011511977,0.00013977745,0.000035145295,0.00004482159,0.0000018635544],"about_ca_topic_score_codex":0.0011304962,"about_ca_topic_score_gemma":0.0011979983,"teacher_disagreement_score":0.0013790341,"about_ca_system_score_codex":0.00013745212,"about_ca_system_score_gemma":0.00015954807,"threshold_uncertainty_score":0.00461334},"labels":[],"label_agreement":null},{"id":"W4382995246","doi":"10.1177/17562864231182934","title":"Cardiac therapies for Duchenne muscular dystrophy","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Muscular Dystrophy Canada; Alberta Innovates; Women and Children's Health Research Institute; Children's Health Research Institute","keywords":"Medicine; Duchenne muscular dystrophy; Dystrophin; Intensive care medicine; Disease; Bioinformatics; Cardiomyopathy; Exon skipping; Clinical trial; Muscular dystrophy; Genetic enhancement; Genome editing; CRISPR; Internal medicine; Heart failure; Exon; Gene","score_opus":0.03475826749725864,"score_gpt":0.3471559604144085,"score_spread":0.31239769291714986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382995246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002368227,0.9974476,0.00019123057,0.0002026249,0.00020285945,0.000007384413,0.000028653976,0.000012000657,0.0016708856],"genre_scores_gemma":[0.001108882,0.99690396,0.00031018225,0.000253505,0.000119407545,0.000011519052,0.00006375707,0.0000030142896,0.0012256532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998816,0.000018483637,0.00001774177,0.000019036393,0.00005041485,0.000012651015],"domain_scores_gemma":[0.9998858,0.00005959576,0.000016618165,0.0000034780187,0.000023801673,0.0000107592905],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030795057,0.00061097887,0.0008288677,0.0017833886,0.00025414865,0.00059218425,0.0005641755,0.000828325,0.0051025073],"category_scores_gemma":[0.0003434992,0.00017298227,0.0005688035,0.00089734234,0.00022225418,0.00061907765,0.000535415,0.0018162767,0.002075402],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007553158,0.00010366267,0.00009060453,0.0138198,0.00006947003,0.00030383252,0.00005870771,0.00029369956,0.0041031777,0.0028114847,0.0250252,0.95324486],"study_design_scores_gemma":[0.00002394851,0.00013653371,0.00067443796,0.0034651367,0.00010337822,0.0015947816,0.00003159383,0.00007562569,0.0009122365,0.001264564,0.9917035,0.000014283434],"about_ca_topic_score_codex":0.0005330172,"about_ca_topic_score_gemma":0.0014284492,"teacher_disagreement_score":0.0051025073,"about_ca_system_score_codex":0.00033658167,"about_ca_system_score_gemma":0.00047970426,"threshold_uncertainty_score":0.017069638},"labels":[],"label_agreement":null},{"id":"W4386928780","doi":"10.1177/17562864231195513","title":"A <i>post hoc</i> evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Jazz Pharmaceuticals; Teva Pharmaceutical Industries; Biogen; Sanofi; Jazz Pharmaceuticals Canada; Pfizer","keywords":"Spasticity; Medicine; Multiple sclerosis; Physical medicine and rehabilitation; Post-hoc analysis; Neuroscience; Post hoc; Physical therapy; Internal medicine; Psychiatry; Psychology","score_opus":0.05747565638420654,"score_gpt":0.3156648069380463,"score_spread":0.2581891505538398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386928780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90305257,0.011730042,0.01366201,0.0017246403,0.0049441135,0.037012894,0.014269572,0.0009916137,0.0126125645],"genre_scores_gemma":[0.92932653,0.0010131663,0.010701894,0.0017867791,0.0006135671,0.046783242,0.004739718,0.00025772335,0.0047774888],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.97483134,0.015385991,0.002287764,0.0037526053,0.002198974,0.0015432419],"domain_scores_gemma":[0.9580539,0.024413187,0.008208356,0.0047248597,0.0034800856,0.001119715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.025532981,0.003331608,0.0068660635,0.0012392994,0.00081621093,0.0020027289,0.0016209787,0.0025380321,0.016682733],"category_scores_gemma":[0.046055485,0.0011193057,0.01987566,0.0010211563,0.0018336034,0.0020356285,0.0024596434,0.0035910527,0.0016736351],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8774595,0.0016751924,0.010367158,0.008712959,0.07495171,0.00021212123,0.00036216626,0.00091978256,0.006845509,0.00049578585,0.004530227,0.013467876],"study_design_scores_gemma":[0.27725863,0.30227566,0.16405784,0.0017491033,0.21344584,0.0005299881,0.000840567,0.0066612535,0.010856875,0.0020038923,0.019912278,0.00040812188],"about_ca_topic_score_codex":0.0012100413,"about_ca_topic_score_gemma":0.0019071656,"teacher_disagreement_score":0.025532981,"about_ca_system_score_codex":0.0015215955,"about_ca_system_score_gemma":0.001980777,"threshold_uncertainty_score":0.13503289},"labels":[],"label_agreement":null},{"id":"W4386939132","doi":"10.1177/17562864231194823","title":"Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; University of British Columbia","funders":"Sanofi","keywords":"Medicine; Alemtuzumab; Multiple sclerosis; Relapsing remitting; Topaz; Open label; Oncology; Internal medicine; Adverse effect; Intensive care medicine; Immunology","score_opus":0.11936048497369685,"score_gpt":0.36085303580033307,"score_spread":0.24149255082663623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386939132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952502,0.002288564,0.00019269134,0.000114596616,0.000027927668,0.00022759284,0.0012502861,0.00003560932,0.000612538],"genre_scores_gemma":[0.99616855,0.000611321,0.000270985,0.00014892036,0.00006956326,0.00017097154,0.0020805248,0.000010584592,0.0004685239],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9983974,0.00077631883,0.00010610484,0.00021435648,0.00032587542,0.00017989172],"domain_scores_gemma":[0.996986,0.0004927675,0.0010974717,0.0002956601,0.0004235042,0.00070468255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053884382,0.00086107256,0.0014176955,0.0003652326,0.00039979006,0.001237516,0.00073575834,0.0008510343,0.0013109334],"category_scores_gemma":[0.0029671704,0.00024200938,0.0014898685,0.00045374746,0.0005386339,0.0008481361,0.00055630703,0.0011439981,0.00037171433],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.744891,0.008454879,0.12707952,0.0007360094,0.0071661146,0.00021749114,0.0003753973,0.0018916683,0.007368567,0.00013723184,0.003188021,0.098494224],"study_design_scores_gemma":[0.19228046,0.1335819,0.65524954,0.00011117249,0.006785209,0.00045570286,0.00018461417,0.0022079446,0.00358771,0.00025165727,0.005206497,0.000097620235],"about_ca_topic_score_codex":0.001641851,"about_ca_topic_score_gemma":0.0014126713,"teacher_disagreement_score":0.0053884382,"about_ca_system_score_codex":0.0008114116,"about_ca_system_score_gemma":0.000859846,"threshold_uncertainty_score":0.0284971},"labels":[],"label_agreement":null},{"id":"W4390639097","doi":"10.1177/17562864231221324","title":"Tenecteplase for the treatment of acute ischemic stroke in the extended time window: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Heart and Stroke Foundation of Canada","keywords":"Medicine; Modified Rankin Scale; Tenecteplase; Odds ratio; Meta-analysis; Thrombolysis; Randomized controlled trial; Confidence interval; Internal medicine; Stroke (engine); Fibrinolytic agent; Relative risk; Tissue plasminogen activator; Ischemic stroke; Ischemia; Myocardial infarction","score_opus":0.051828240869509865,"score_gpt":0.37105878754380517,"score_spread":0.3192305466742953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390639097","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029546337,0.995663,0.00034295686,0.00014479432,0.00010473168,0.00025731514,0.00033286677,0.000016166958,0.00018357701],"genre_scores_gemma":[0.080096856,0.9159285,0.0013908413,0.00061735284,0.00019169273,0.0010272806,0.0005193459,0.000016724063,0.00021155327],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99463755,0.0023121103,0.0016934001,0.00054499815,0.0006180855,0.00019381766],"domain_scores_gemma":[0.988304,0.008227693,0.0021790906,0.00027008995,0.00084248435,0.0001766371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009308254,0.00225106,0.018151658,0.005992165,0.0005032075,0.0027271397,0.001887953,0.0018164762,0.003546323],"category_scores_gemma":[0.018373258,0.0010656451,0.02919004,0.006910056,0.00060009555,0.0015834407,0.0011827737,0.0015520154,0.0002563821],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024129404,0.000041481075,0.0016120999,0.557742,0.42154893,0.00012331034,0.0000689673,0.00044560008,0.0002368585,0.00013229661,0.000562786,0.015072786],"study_design_scores_gemma":[0.00077971426,0.00026340463,0.002309749,0.03607818,0.9581975,0.00009400262,0.000042205513,0.00015804768,0.00010423346,0.00017413952,0.0017764687,0.000022220625],"about_ca_topic_score_codex":0.0053189415,"about_ca_topic_score_gemma":0.011567431,"teacher_disagreement_score":0.018151658,"about_ca_system_score_codex":0.0021773125,"about_ca_system_score_gemma":0.0036166713,"threshold_uncertainty_score":0.049227297},"labels":[],"label_agreement":null},{"id":"W4391053875","doi":"10.1177/17562864231218181","title":"Effect of altered gene expression in lipid metabolism on cognitive improvement in patients with Alzheimer’s dementia following fecal microbiota transplantation: a preliminary study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Research Foundation of Korea; National Research Foundation","keywords":"Dementia; Gut flora; Medicine; Montreal Cognitive Assessment; Cognitive decline; Feces; Transplantation; Microbiome; Clinical Dementia Rating; Internal medicine; Biology; Physiology; Immunology; Bioinformatics; Disease; Microbiology","score_opus":0.007089060045650178,"score_gpt":0.2823228089757372,"score_spread":0.275233748930087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391053875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99928564,0.0003330383,0.00008082688,0.00001786028,0.000008623005,0.000020175294,0.000066820416,0.000003517699,0.00018360313],"genre_scores_gemma":[0.9989182,0.00023298169,0.00028916064,0.000043654727,0.000019373996,0.00003612373,0.00019045848,0.000001467452,0.00026854672],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99986875,0.000033250104,0.000011092774,0.0000345814,0.000023551562,0.00002872287],"domain_scores_gemma":[0.9997466,0.000044094035,0.000063186126,0.000018484774,0.000051828185,0.000075757074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003687432,0.00036025658,0.0005106095,0.00045916648,0.000302417,0.0003361252,0.00011373509,0.00030729597,0.0008670924],"category_scores_gemma":[0.00040745075,0.000096598276,0.00042067046,0.00031402815,0.0002731596,0.00015642398,0.00018272342,0.0003386842,0.00013725487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07044163,0.009814539,0.63561934,0.0003950285,0.0006843907,0.0029156941,0.00084327336,0.00020475582,0.20604134,0.000057500296,0.00042641175,0.07255602],"study_design_scores_gemma":[0.00027035372,0.016559277,0.9745515,0.000011994635,0.00026542184,0.0007375712,0.00024976078,0.00024652117,0.0065550725,0.0000452212,0.000494741,0.000012483371],"about_ca_topic_score_codex":0.0006181352,"about_ca_topic_score_gemma":0.0008523827,"teacher_disagreement_score":0.0008670924,"about_ca_system_score_codex":0.0002361491,"about_ca_system_score_gemma":0.00021393794,"threshold_uncertainty_score":0.0029007196},"labels":[],"label_agreement":null},{"id":"W4392157493","doi":"10.1177/17562864231221331","title":"Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Health and Medical Research Council; Sanofi Genzyme; Grifols; Všeobecná Fakultní Nemocnice v Praze; Sanofi; European Commission; Canadian Institutes of Health Research; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Univerzita Karlova v Praze; Medical Research Council; Biogen; Celgene","keywords":"Natalizumab; Medicine; Multiple sclerosis; Disease; Fingolimod; First line therapy; Glatiramer acetate; Clinical significance; Teriflunomide; Intensive care medicine; Oncology; Internal medicine; Immunology","score_opus":0.09250910395706537,"score_gpt":0.36120260786897235,"score_spread":0.268693503911907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392157493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996302,0.00020115526,0.000025930987,0.000011779547,0.000004047166,0.000005557227,0.000054238342,5.9222333e-7,0.000066442546],"genre_scores_gemma":[0.9996592,0.00006987248,0.000029160648,0.000016986674,0.000008111385,0.000008115548,0.00016448504,3.4527295e-7,0.00004377703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999527,0.00013087234,0.000068051515,0.00013237236,0.00006773438,0.00007405777],"domain_scores_gemma":[0.99860317,0.00022664688,0.0007714292,0.00010443295,0.00006244629,0.00023191747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008440692,0.00016870454,0.00046435156,0.00038045138,0.00030123547,0.00048224488,0.00022294163,0.00038586213,0.0007091472],"category_scores_gemma":[0.0026379244,0.00019369053,0.0006646509,0.00041732573,0.00020602254,0.00036350603,0.00029576162,0.0004222709,0.000113017544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070677046,0.00020658021,0.9871209,0.000024591702,0.0004564792,0.00012746776,0.00007294108,0.00025687952,0.00061669166,0.00004228828,0.00008517437,0.0039222245],"study_design_scores_gemma":[0.0004562381,0.0032379706,0.9940546,0.000016681628,0.00043245422,0.0003593068,0.0001197968,0.00072598,0.0002524882,0.000070300775,0.0002636607,0.000010553853],"about_ca_topic_score_codex":0.0014543232,"about_ca_topic_score_gemma":0.001264919,"teacher_disagreement_score":0.0014543232,"about_ca_system_score_codex":0.00035414065,"about_ca_system_score_gemma":0.00024998194,"threshold_uncertainty_score":0.0044639707},"labels":[],"label_agreement":null},{"id":"W4392848466","doi":"10.1177/17562864241233044","title":"Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Multiple Sclerosis Society; Research Manitoba; Multiple Sclerosis Trust; Multiple Sclerosis Society of Canada; Arthritis Society; Alexion Pharmaceuticals; Celgene; Biogen; Gemeinsame Bundesausschuss; Sanofi; U.S. Department of Defense","keywords":"Medicine; Multiple sclerosis; Observational study; Fingolimod; Disease; Proportional hazards model; Patient registry; Internal medicine; Adverse effect; Pediatrics; Emergency medicine; Immunology","score_opus":0.17047351675556285,"score_gpt":0.3773027207272071,"score_spread":0.20682920397164425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392848466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8595734,0.1338503,0.0020286308,0.0003365173,0.0001060478,0.00021970914,0.0031372858,0.00007096408,0.000677134],"genre_scores_gemma":[0.9894078,0.008028136,0.000914202,0.00011062625,0.000040628212,0.00014987943,0.0012765875,0.000013007719,0.000059167396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98876524,0.005955057,0.0020284785,0.0018870481,0.001023853,0.00034041548],"domain_scores_gemma":[0.9789844,0.010474161,0.0074131885,0.0016121916,0.0011226288,0.00039354197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02375936,0.0011793328,0.002715369,0.0042191586,0.00041690128,0.0021523149,0.00129905,0.0010735692,0.00077717524],"category_scores_gemma":[0.025195044,0.00093286886,0.016428323,0.0056241606,0.0005064708,0.00082937855,0.0015331272,0.000974494,0.000100538586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006111731,0.00012744612,0.78536385,0.004673096,0.1883366,0.00013915297,0.0003889867,0.0009767705,0.00031891125,0.00017244708,0.0004670133,0.012923977],"study_design_scores_gemma":[0.0015262896,0.0010676086,0.7883811,0.0012540281,0.20320551,0.00036907863,0.000395443,0.0017546999,0.00035052805,0.0004405923,0.0011879989,0.00006707929],"about_ca_topic_score_codex":0.010370182,"about_ca_topic_score_gemma":0.010240237,"teacher_disagreement_score":0.02375936,"about_ca_system_score_codex":0.0011339097,"about_ca_system_score_gemma":0.001355962,"threshold_uncertainty_score":0.12565303},"labels":[],"label_agreement":null},{"id":"W4393121545","doi":"10.1177/17562864241239453","title":"Comparative efficacy of ofatumumab <i>versus</i> oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Novartis Australia","keywords":"Fingolimod; Medicine; Cladribine; Ofatumumab; Teriflunomide; Placebo; Internal medicine; Multiple sclerosis; Natalizumab; Disease; Alternative medicine; Immunology; Rituximab; Pathology","score_opus":0.3913923956294829,"score_gpt":0.44032755044416655,"score_spread":0.048935154814683635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393121545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94166535,0.0066487417,0.041836444,0.00094764575,0.00028499324,0.0023594215,0.0031602322,0.00012706075,0.002970147],"genre_scores_gemma":[0.990965,0.00057560834,0.005955874,0.00017520727,0.000062978565,0.0009605269,0.0009712224,0.000010757554,0.00032284114],"study_design_codex":"simulation_or_modeling","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.97101665,0.024793753,0.0011356291,0.0017401614,0.0008020154,0.0005117168],"domain_scores_gemma":[0.9196898,0.068355456,0.006932793,0.0031516738,0.0010006198,0.00086968526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.050433032,0.0013033883,0.0032980838,0.0015059321,0.00033702864,0.0020524256,0.001462417,0.0014736489,0.0041075274],"category_scores_gemma":[0.05560048,0.0005225121,0.012545428,0.0011083431,0.0011542818,0.0012886788,0.001509872,0.0021818879,0.00025970762],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2016043,0.002756893,0.11320367,0.00364877,0.12211552,0.00028582863,0.00041203073,0.46880126,0.001414756,0.013148419,0.002348025,0.0702605],"study_design_scores_gemma":[0.040902264,0.054397635,0.058222752,0.0006144277,0.06755833,0.00029402706,0.00030320717,0.74084646,0.0025128264,0.030166328,0.0039093844,0.00027240114],"about_ca_topic_score_codex":0.0019449985,"about_ca_topic_score_gemma":0.0009624844,"teacher_disagreement_score":0.050433032,"about_ca_system_score_codex":0.0014402048,"about_ca_system_score_gemma":0.0017211952,"threshold_uncertainty_score":0.2667185},"labels":[],"label_agreement":null},{"id":"W4393309179","doi":"10.1177/17562864241239101","title":"Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a <i>post hoc</i> analysis","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Serono Symposia International Foundation; International Progressive MS Alliance; National Research Foundation; Universität Basel; Celgene; Alnylam Pharmaceuticals; Teva Pharmaceutical Industries; Biogen; Sanofi; Merck","keywords":"Medicine; Post-hoc analysis; Multiple sclerosis; Confidence interval; Hazard ratio; Internal medicine; Proportional hazards model; Magnetic resonance imaging; Relapsing remitting; McDonald criteria; Placebo; Gastroenterology; Pathology; Immunology; Radiology","score_opus":0.031800728844806815,"score_gpt":0.37541925881852567,"score_spread":0.34361852997371883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393309179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99847823,0.0001574492,0.00053253555,0.000024992414,0.000029955369,0.00009953102,0.0002777534,0.000012394203,0.00038712576],"genre_scores_gemma":[0.99853563,0.00002939098,0.0003398979,0.00002950393,0.00003278044,0.00014532817,0.00045892125,0.000009206421,0.0004193146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980332,0.0009073629,0.00010190548,0.00046959703,0.00021462637,0.0002731742],"domain_scores_gemma":[0.99585116,0.0023238936,0.00065015716,0.00051904796,0.00028840866,0.00036739453],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004013576,0.0007541336,0.0014089443,0.0004150156,0.00025600815,0.00066038483,0.0006573914,0.00048167427,0.002525922],"category_scores_gemma":[0.0035571267,0.00031677436,0.0030734858,0.00037204457,0.00038046748,0.00065847056,0.0004886148,0.0010943334,0.0002817919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2620491,0.0020464335,0.70897055,0.00024789883,0.010087655,0.00043487313,0.00022415277,0.0014869866,0.004599402,0.00016949576,0.00096836075,0.008715118],"study_design_scores_gemma":[0.008762469,0.08576356,0.8792069,0.000031840813,0.008657406,0.00046288033,0.00031672596,0.011340283,0.002938175,0.0002600072,0.0021993043,0.00006039934],"about_ca_topic_score_codex":0.0009085303,"about_ca_topic_score_gemma":0.00071996613,"teacher_disagreement_score":0.004013576,"about_ca_system_score_codex":0.00041819309,"about_ca_system_score_gemma":0.00062941987,"threshold_uncertainty_score":0.021226108},"labels":[],"label_agreement":null},{"id":"W4394896461","doi":"10.1177/17562864241243186","title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Chugai Pharmaceutical; Horizon Therapeutics; Genentech; Grifols; Mitsubishi Tanabe Pharma Corporation; Warszawski Uniwersytet Medyczny; CSL Behring; National Institute for Health and Care Research; Regeneron Pharmaceuticals; National Institutes of Health; UCB Pharma; Argenx; Cytokinetics; Japan Blood Products Organization; Union Chimique Belge; Alexion Pharmaceuticals; Patient-Centered Outcomes Research Institute; Biogen; Centers for Disease Control and Prevention; Muscular Dystrophy Association; Uniwersytet Warszawski; Momenta Pharmaceuticals; Sanofi; AstraZeneca; Myasthenia Gravis Foundation of America","keywords":"Medicine; Myasthenia gravis; Interim; Interim analysis; Open label; Term (time); Extension (predicate logic); Adverse effect; Clinical trial; Internal medicine; Law; Computer science","score_opus":0.02397615723265628,"score_gpt":0.329973967553128,"score_spread":0.30599781032047174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394896461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99459153,0.0014377526,0.0008315084,0.00014973647,0.000043808595,0.0007504907,0.0011062076,0.000058946807,0.001030146],"genre_scores_gemma":[0.99466974,0.00038188352,0.00088308554,0.00032438792,0.00008605906,0.0007044635,0.0020647647,0.000014316543,0.0008713045],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99872786,0.00065055327,0.00008235847,0.00015389625,0.00017591046,0.00020937054],"domain_scores_gemma":[0.9974733,0.0006914719,0.00081720314,0.00041067382,0.00016852381,0.0004387555],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005684379,0.0008966543,0.002084227,0.00030281025,0.00035461228,0.0010385871,0.00045778084,0.00093420217,0.0018622865],"category_scores_gemma":[0.0026486483,0.0003200413,0.0024962611,0.0002932624,0.0005730964,0.00077567186,0.00038706468,0.0022188472,0.0005260321],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87123704,0.011029885,0.037955817,0.00038976557,0.003114154,0.00032330933,0.00019664977,0.001867916,0.016047202,0.00014853688,0.001605686,0.056084078],"study_design_scores_gemma":[0.32691035,0.47369602,0.18195689,0.00006758914,0.0050913272,0.0005293002,0.000102532336,0.002884594,0.0054711564,0.00036258806,0.0028585643,0.0000691129],"about_ca_topic_score_codex":0.00022930415,"about_ca_topic_score_gemma":0.00039630703,"teacher_disagreement_score":0.005684379,"about_ca_system_score_codex":0.00047842655,"about_ca_system_score_gemma":0.0007127835,"threshold_uncertainty_score":0.030062199},"labels":[],"label_agreement":null},{"id":"W4396242288","doi":"10.1177/17562864241246938","title":"Overview of systematic reviews comparing endovascular to best medical treatment for large-vessel occlusion acute ischaemic stroke: an umbrella review","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Randomized controlled trial; Modified Rankin Scale; Systematic review; Meta-analysis; MEDLINE; Confidence interval; Relative risk; Stroke (engine); Cochrane Library; Internal medicine; Physical therapy; Ischemic stroke; Ischemia","score_opus":0.0994132575965261,"score_gpt":0.40835839606508734,"score_spread":0.30894513846856125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396242288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022856356,0.9980502,0.0002286693,0.0003853953,0.00016592062,0.00036623725,0.00033212636,0.000011861358,0.00023103406],"genre_scores_gemma":[0.004488757,0.99185646,0.0011196919,0.0007267179,0.00017085405,0.001222395,0.00027486292,0.00000943411,0.00013089331],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9785033,0.00816772,0.008284843,0.0013720986,0.0032338155,0.00043828547],"domain_scores_gemma":[0.95241463,0.032960624,0.009736437,0.00076154835,0.0037109896,0.00041586286],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017781513,0.0028687445,0.013487905,0.024017388,0.00092557096,0.0037773652,0.0022957264,0.0026033104,0.005958187],"category_scores_gemma":[0.06861745,0.0018975161,0.00999226,0.018436119,0.0011995175,0.0036349765,0.0024667694,0.0015990104,0.0007101017],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000102828046,0.000007933521,0.00023715281,0.9674489,0.0074789487,0.000044135286,0.00009069966,0.000070383925,0.00011712405,0.00030473538,0.001897017,0.022200158],"study_design_scores_gemma":[0.00012540948,0.00011094316,0.0014352875,0.9219626,0.052288827,0.00015623844,0.00010861736,0.00007457185,0.00013212083,0.00051997567,0.023059664,0.000025580495],"about_ca_topic_score_codex":0.005908223,"about_ca_topic_score_gemma":0.01673301,"teacher_disagreement_score":0.024017388,"about_ca_system_score_codex":0.0053677773,"about_ca_system_score_gemma":0.012660168,"threshold_uncertainty_score":0.094038725},"labels":[],"label_agreement":null},{"id":"W4402546531","doi":"10.1177/17562864241273045","title":"The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hotchkiss Brain Institute; University of Manitoba; Providence Health Care; University of British Columbia; University of Calgary; Centre Hospitalier de l’Université de Montréal; University of Toronto; Women and Children’s Health Research Institute; University of Alberta; Centre for Advancing Health Outcomes; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada; Michael Smith Health Research BC; Horizon Therapeutics; U.S. Department of Defense; Sanofi; Government of Alberta; Fondation Brain Canada; Teva Pharmaceutical Industries; Biogen; University of Toronto; Biogen Idec; Eli Lilly and Company; Arthritis Society; International Progressive MS Alliance; Roche; University of Calgary","keywords":"Medicine; Multiple sclerosis; Prospective cohort study; Baseline (sea); Cohort; Internal medicine; Oncology; Immunology","score_opus":0.057016722251758495,"score_gpt":0.3518034886168417,"score_spread":0.29478676636508316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402546531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8338368,0.006013041,0.0013296942,0.001846815,0.00014079001,0.0015245652,0.13852873,0.00007247594,0.01670711],"genre_scores_gemma":[0.9553885,0.0023574205,0.0017811102,0.00043005493,0.000047435085,0.0009341965,0.03620359,0.000024515912,0.0028332027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981762,0.00017953705,0.00011906816,0.0003092401,0.0008882496,0.00032764283],"domain_scores_gemma":[0.99733704,0.00011799812,0.00040529162,0.00016169519,0.0014741496,0.0005038037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020837907,0.00049793604,0.0006717738,0.0018546777,0.003192454,0.0010368164,0.0010823425,0.0006495979,0.0030069263],"category_scores_gemma":[0.00405657,0.00030194566,0.00074811705,0.005722137,0.00045713724,0.00045558726,0.0007061888,0.0010614429,0.00035371128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030115343,0.000047328926,0.98444057,0.000118797594,0.00027849243,0.00010913141,0.0003041117,0.00013741155,0.00019859293,0.00028093107,0.008281937,0.0055014994],"study_design_scores_gemma":[0.000038639268,0.000027652764,0.9960634,0.0000426344,0.000067724824,0.000081672966,0.00016696453,0.00009779273,0.000018244518,0.000049471724,0.0033357164,0.00001007703],"about_ca_topic_score_codex":0.94607043,"about_ca_topic_score_gemma":0.9633375,"teacher_disagreement_score":0.053929567,"about_ca_system_score_codex":0.009441702,"about_ca_system_score_gemma":0.019894926,"threshold_uncertainty_score":0.10849428},"labels":[],"label_agreement":null},{"id":"W4402546568","doi":"10.1177/17562864241273036","title":"Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"EMD Serono; Schweizerische Multiple Sklerose Gesellschaft; F. Hoffmann-La Roche; Grifols; Fondazione Cariplo; Multiple Sclerosis Society; UCB Pharma; Argenx; Idorsia Pharmaceuticals; Amicus Therapeutics; Janssen Pharmaceuticals; Merck KGaA; Bristol-Myers Squibb; CSL Behring; Pfizer; Biogen; Celgene; H. Lundbeck A/S; Alnylam Pharmaceuticals; Alexion Pharmaceuticals; Regeneron Pharmaceuticals; Novo Nordisk; Teva Pharmaceutical Industries; Sanofi","keywords":"Medicine; Myasthenia gravis; Autoantibody; Placebo; Subgroup analysis; Internal medicine; Tyrosine kinase; Gastroenterology; Antibody; Immunology; Oncology; Pharmacology; Meta-analysis; Receptor; Pathology; Alternative medicine","score_opus":0.015232509837930777,"score_gpt":0.2854096034517853,"score_spread":0.2701770936138545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402546568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804391,0.014675923,0.00065665966,0.00043072595,0.00030437956,0.001629994,0.00076367694,0.000061652965,0.0010378922],"genre_scores_gemma":[0.9951265,0.0021415912,0.0004157294,0.00036945194,0.00019578284,0.0007982232,0.00047905953,0.000011839859,0.00046177176],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983467,0.0009607796,0.0002213674,0.00019950228,0.000113774266,0.00015789727],"domain_scores_gemma":[0.99845374,0.0005849996,0.0004106265,0.00018403554,0.00010015471,0.00026647552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003762526,0.0015175894,0.0050213956,0.0004876284,0.00035304762,0.0012206946,0.00074480503,0.0015109809,0.0026653036],"category_scores_gemma":[0.0029954636,0.000617617,0.005363937,0.0004252367,0.00069098646,0.00079594343,0.00043031562,0.0016482569,0.0004687434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9723717,0.0010228987,0.0019220184,0.0009670738,0.0065172175,0.00006670137,0.00005727196,0.0003615957,0.0040926365,0.000043938366,0.00029866095,0.01227822],"study_design_scores_gemma":[0.92035645,0.0599661,0.010011996,0.00008326486,0.00765278,0.00009117303,0.0000521089,0.0005019751,0.0005407671,0.00015972916,0.00055024296,0.000033449134],"about_ca_topic_score_codex":0.00056879106,"about_ca_topic_score_gemma":0.0018050985,"teacher_disagreement_score":0.0050213956,"about_ca_system_score_codex":0.0007100371,"about_ca_system_score_gemma":0.0008050968,"threshold_uncertainty_score":0.019898415},"labels":[],"label_agreement":null},{"id":"W4402696194","doi":"10.1177/17562864241276204","title":"Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Collaboration On Repair Discoveries; University of British Columbia; McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Ibrutinib; Odds ratio; Ofatumumab; Internal medicine; Epilepsy; Oncology; Adverse Event Reporting System; Population; Discontinuation; Adverse effect; Rituximab; Psychiatry; Leukemia; Lymphoma; Chronic lymphocytic leukemia","score_opus":0.07818901370015804,"score_gpt":0.3082756776405036,"score_spread":0.23008666394034558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402696194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901986,0.0053423643,0.00054721226,0.00018717442,0.000011622627,0.000035092005,0.0022157524,0.00000853827,0.001453651],"genre_scores_gemma":[0.9985637,0.00049614714,0.00019640553,0.00005039125,0.000015641834,0.00002076814,0.00054473226,0.0000018494437,0.00011050139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782735,0.00079507416,0.00045900926,0.00034498656,0.00039904902,0.00017447646],"domain_scores_gemma":[0.9887034,0.0037392138,0.0066692843,0.00036351534,0.00027680886,0.00024775625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023169322,0.00017419303,0.00036320987,0.0011467744,0.0001459004,0.00039646236,0.0002645933,0.00025636866,0.002457584],"category_scores_gemma":[0.0060042674,0.00008697308,0.0007827664,0.0016529111,0.00015088877,0.00032316896,0.0004000495,0.0003867823,0.00013323211],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005169201,0.00001475752,0.9950708,0.00008292888,0.0004592228,0.000034806562,0.0000140637385,0.000057284615,0.00017746023,0.000029087574,0.00008615537,0.0034565122],"study_design_scores_gemma":[0.000026596115,0.00019421957,0.9978993,0.00002430426,0.0003608453,0.0003323936,0.000027292726,0.00022194936,0.00023414484,0.000052169595,0.00062412606,0.0000026832013],"about_ca_topic_score_codex":0.0015159133,"about_ca_topic_score_gemma":0.0016432154,"teacher_disagreement_score":0.002457584,"about_ca_system_score_codex":0.00028735254,"about_ca_system_score_gemma":0.00038843014,"threshold_uncertainty_score":0.012253284},"labels":[],"label_agreement":null},{"id":"W4402890485","doi":"10.1177/17562864241281903","title":"Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Liraglutide; Semaglutide; Internal medicine; Mace; Overweight; Odds ratio; Diabetes mellitus; Type 2 diabetes; Placebo; Dulaglutide; Myocardial infarction; Population; Glucagon-like peptide 1 receptor; Endocrinology; Adverse effect; Obesity; Agonist; Receptor; Percutaneous coronary intervention","score_opus":0.06532569228572091,"score_gpt":0.3519981919897024,"score_spread":0.28667249970398145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402890485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0087366635,0.9896214,0.00036871317,0.00016219504,0.00010716276,0.00020055518,0.0005050523,0.00002122672,0.0002769496],"genre_scores_gemma":[0.23264132,0.76263726,0.0016526816,0.0008046696,0.0002635738,0.00083642075,0.00087957276,0.000026585758,0.00025798252],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99283147,0.0031504456,0.002149114,0.00086902094,0.0007894008,0.00021053385],"domain_scores_gemma":[0.9877423,0.0078827515,0.0028832557,0.00033642084,0.00096292014,0.00019223758],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009750518,0.002198055,0.016865348,0.0045535993,0.00049804477,0.0024616497,0.0017306901,0.001880344,0.002392753],"category_scores_gemma":[0.020111203,0.0014174174,0.034938175,0.0052676764,0.00068217446,0.0012218935,0.0011282574,0.0015962321,0.00022606528],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033530612,0.000035038083,0.0051735453,0.3303055,0.6489049,0.00011149542,0.00006143953,0.00053349667,0.00026542903,0.00009779723,0.0004576817,0.010700581],"study_design_scores_gemma":[0.00078228506,0.00020405227,0.0033768022,0.014464175,0.97986823,0.000080585676,0.000026846514,0.00016237838,0.00010470876,0.0000947939,0.0008166097,0.000018453786],"about_ca_topic_score_codex":0.0047237105,"about_ca_topic_score_gemma":0.0100344755,"teacher_disagreement_score":0.016865348,"about_ca_system_score_codex":0.001849593,"about_ca_system_score_gemma":0.0023827006,"threshold_uncertainty_score":0.051566243},"labels":[],"label_agreement":null},{"id":"W4403258165","doi":"10.1177/17562864241283328","title":"Clinical and ethical challenges in decision-making for patients with disorders of consciousness and locked-in syndrome from Chinese neurologists’ perspectives","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Traumatic Brain Injury Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Key Research and Development Program of China; Fonds De La Recherche Scientifique - FNRS; Natural Science Foundation of Zhejiang Province; Hangzhou Normal University; National Natural Science Foundation of China","keywords":"Medicine; Persistent vegetative state; Consciousness; Psychiatry; Minimally conscious state; Intensive care medicine; Neuroscience; Psychology","score_opus":0.039950785971992586,"score_gpt":0.3939442022738692,"score_spread":0.35399341630187664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403258165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88251436,0.0052551185,0.0005479496,0.10280975,0.00031383501,0.00006142098,0.000044815268,0.0000070286424,0.008445721],"genre_scores_gemma":[0.9917048,0.0015015664,0.00025969988,0.0061630188,0.00013193775,0.000023531295,0.000014319351,0.0000018909467,0.00019916403],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.98153174,0.01269069,0.0011778518,0.0004926246,0.0019285699,0.0021786066],"domain_scores_gemma":[0.96540713,0.017074576,0.0077900672,0.0005414427,0.0032762755,0.0059105563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01870749,0.0003287143,0.0004748846,0.0011743105,0.006415373,0.004318705,0.0010771608,0.0023669729,0.001702195],"category_scores_gemma":[0.041851215,0.0003248986,0.0005631818,0.0010960919,0.008132355,0.0029511114,0.0032441807,0.0032844986,0.00013925393],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029046577,0.00021524365,0.31303388,0.000838613,0.00017713533,0.013306466,0.58716375,0.00045469886,0.0011988806,0.008263997,0.017195493,0.057861373],"study_design_scores_gemma":[0.00009551113,0.00021972432,0.12374325,0.0014442183,0.00013139923,0.0065579866,0.83738744,0.0010921335,0.00039571375,0.0071905493,0.021537457,0.00020464255],"about_ca_topic_score_codex":0.020564558,"about_ca_topic_score_gemma":0.02796712,"teacher_disagreement_score":0.020564558,"about_ca_system_score_codex":0.007850294,"about_ca_system_score_gemma":0.017781448,"threshold_uncertainty_score":0.09893584},"labels":[],"label_agreement":null},{"id":"W4403721828","doi":"10.1177/17562864241284166","title":"The impact of different lifestyle factors on disability in multiple sclerosis at older ages: a monocentric retrospective study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Multiple sclerosis; Medicine; Disease; Central nervous system; Gerontology; Pediatrics; Physical therapy; Internal medicine; Immunology","score_opus":0.061238697300212044,"score_gpt":0.35909734275134975,"score_spread":0.2978586454511377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403721828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99953663,0.00019237834,0.000057463232,0.0000046419477,0.0000017106535,0.000012419748,0.000100366764,7.828134e-7,0.00009364379],"genre_scores_gemma":[0.9995454,0.000120904144,0.00007323059,0.00001587482,0.0000074129894,0.00001578933,0.00015197192,9.6932e-7,0.00006841535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920875,0.00021972288,0.00010104703,0.00020775424,0.00013462578,0.00012823682],"domain_scores_gemma":[0.998365,0.0002580425,0.00070374523,0.00018184305,0.00021845297,0.00027283948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011893269,0.0003692901,0.0006480143,0.001369216,0.0006061711,0.0004894879,0.00026729138,0.00045326605,0.0010116233],"category_scores_gemma":[0.0016022255,0.00041846005,0.0005262568,0.0014569161,0.00030592093,0.00044606318,0.0005509899,0.00025366084,0.00018357615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014971,0.00003885536,0.998602,0.00001584443,0.000044929922,0.00013425165,0.00011408632,0.000010986814,0.0001737735,0.000006539569,0.000021861562,0.0006871234],"study_design_scores_gemma":[0.000010023824,0.0003285415,0.9988134,0.000005964302,0.000046308123,0.00037254608,0.00021156331,0.000035832156,0.00003796024,0.0000061243036,0.00012832049,0.0000033541523],"about_ca_topic_score_codex":0.0046908925,"about_ca_topic_score_gemma":0.0052639423,"teacher_disagreement_score":0.0046908925,"about_ca_system_score_codex":0.00032366414,"about_ca_system_score_gemma":0.0003273764,"threshold_uncertainty_score":0.009327173},"labels":[],"label_agreement":null},{"id":"W4405574148","doi":"10.1177/17562864241306684","title":"Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance","year":2024,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Sanofi","keywords":"Multiple sclerosis; Medicine; Pathology; Neuroinflammation; Disease; Biomarker; Neuroscience; Bioinformatics; Immunology; Biology","score_opus":0.2637609567356469,"score_gpt":0.45250954053715475,"score_spread":0.18874858380150783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405574148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009227908,0.9734292,0.004285002,0.004592936,0.0026641765,0.00023423567,0.00075918925,0.00009863764,0.004708677],"genre_scores_gemma":[0.05193587,0.90364385,0.02375988,0.004819883,0.0080176825,0.0004928761,0.0036902886,0.00011091372,0.0035287982],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983582,0.00045091021,0.0004546182,0.00021319173,0.0004027433,0.00012029433],"domain_scores_gemma":[0.9979342,0.00055230164,0.00064617884,0.00006124369,0.00060006033,0.00020599789],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025345217,0.0009802614,0.0015570008,0.006032118,0.0006321628,0.0018343034,0.0013409498,0.0010365952,0.0017605057],"category_scores_gemma":[0.0037086993,0.00020352611,0.00061236514,0.0059123384,0.002070937,0.0019702467,0.0014187895,0.0018139224,0.0017126977],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057433406,0.00013833903,0.01951333,0.012530196,0.00023210373,0.0009533549,0.0014491018,0.0004317061,0.006088651,0.014414529,0.0880906,0.85558367],"study_design_scores_gemma":[0.00009996623,0.00071110827,0.06484082,0.013492213,0.00041607657,0.022277065,0.0015264902,0.0007530021,0.0010400581,0.023943543,0.87071794,0.00018166918],"about_ca_topic_score_codex":0.0023533,"about_ca_topic_score_gemma":0.003177657,"teacher_disagreement_score":0.006032118,"about_ca_system_score_codex":0.0012277196,"about_ca_system_score_gemma":0.0023586606,"threshold_uncertainty_score":0.013404012},"labels":[],"label_agreement":null},{"id":"W4411506045","doi":"10.1177/17562864251346326","title":"Therapeutic options for Duchenne muscular dystrophy: hope or hype?","year":2025,"lang":"en","type":"editorial","venue":"Therapeutic Advances in Neurological Disorders","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Duchenne muscular dystrophy; Muscular dystrophy; Intensive care medicine; Neuroscience; Physical medicine and rehabilitation; Internal medicine; Psychology","score_opus":0.009820308100301598,"score_gpt":0.3000819553959397,"score_spread":0.2902616472956381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411506045","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024471494,0.023896528,0.00011576445,0.04327026,0.93090093,0.000010966907,0.000022916714,0.000035588568,0.0017225444],"genre_scores_gemma":[0.0002984727,0.012823796,0.000111347144,0.02813064,0.9530333,0.000014842391,0.000015556147,0.000018110684,0.0055539566],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962035,0.000976954,0.00052734243,0.00034719796,0.0016693778,0.00027562302],"domain_scores_gemma":[0.9836353,0.009211657,0.000747414,0.0003082445,0.0038643833,0.0022330647],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075397016,0.0032866877,0.0039728847,0.002310507,0.002591147,0.006106512,0.003395155,0.017423037,0.010696513],"category_scores_gemma":[0.019930571,0.00092772173,0.0022512667,0.0010917401,0.002973114,0.005070324,0.001546186,0.02924474,0.007160181],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042930955,0.000014333339,0.000013070096,0.00028045484,0.000022978187,0.000115065624,0.000011420322,0.000031623254,0.000042870975,0.00061026093,0.99090767,0.007907273],"study_design_scores_gemma":[0.00008297985,0.00004511532,0.00016146914,0.0007071506,0.00006336587,0.0003461884,0.00004914256,0.00017501386,0.000056219153,0.002149347,0.9961365,0.000027465476],"about_ca_topic_score_codex":0.0018240337,"about_ca_topic_score_gemma":0.005549196,"teacher_disagreement_score":0.017423037,"about_ca_system_score_codex":0.0029506257,"about_ca_system_score_gemma":0.0026721687,"threshold_uncertainty_score":0.039874256},"labels":[],"label_agreement":null},{"id":"W4412808922","doi":"10.1177/17562864251351760","title":"Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Rheinische Friedrich-Wilhelms-Universität Bonn; University of Alberta; McGill University Health Centre; Merck KGaA; McGill University","keywords":"Cladribine; Multiple sclerosis; Medicine; Relapsing remitting; Fingolimod; Oncology; Internal medicine; Immunology","score_opus":0.0542154939765968,"score_gpt":0.3566189088339214,"score_spread":0.3024034148573246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412808922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952296,0.003442164,0.000065568456,0.0000727192,0.000011766767,0.00010646394,0.0005870076,0.000008078216,0.00047669205],"genre_scores_gemma":[0.99681795,0.00093715306,0.0001245831,0.00015327986,0.000056156143,0.00009212026,0.0013862171,0.0000028384861,0.00042952524],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99942684,0.00026386816,0.00005007903,0.00007670283,0.000106267544,0.00007626192],"domain_scores_gemma":[0.99827313,0.0002960226,0.00065380835,0.00017813321,0.00016371947,0.00043516944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029273944,0.0007167708,0.0011682269,0.00028067274,0.0002808269,0.00070367835,0.00032459706,0.0006996258,0.0007855214],"category_scores_gemma":[0.0013607013,0.0002137638,0.0011236538,0.00028146163,0.0003175076,0.00042758722,0.00035256025,0.00066471176,0.00016683467],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6019501,0.009965834,0.26568046,0.0011780445,0.008183772,0.00047065527,0.00051869045,0.0020025037,0.013591745,0.00015866592,0.0025798648,0.0937196],"study_design_scores_gemma":[0.045920897,0.10561171,0.8377044,0.00014291148,0.004318365,0.0004591289,0.00013862237,0.0009214884,0.0021612756,0.00010770563,0.002456965,0.000056473953],"about_ca_topic_score_codex":0.000930013,"about_ca_topic_score_gemma":0.0013436006,"teacher_disagreement_score":0.0029273944,"about_ca_system_score_codex":0.0005202767,"about_ca_system_score_gemma":0.00043453334,"threshold_uncertainty_score":0.01548171},"labels":[],"label_agreement":null},{"id":"W4413436594","doi":"10.1177/17562864251360913","title":"Platelet inhibition strategies in rescue stenting after failed thrombectomy: a large retrospective multicenter registry","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Freiwillige Akademische Gesellschaft","keywords":"Medicine; Retrospective cohort study; Intensive care medicine; Internal medicine","score_opus":0.006398649536665043,"score_gpt":0.27690314426865786,"score_spread":0.27050449473199284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413436594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9992874,0.00027228126,0.000061311766,0.00001993659,0.0000034024058,0.0000081881035,0.00021803596,0.0000022527531,0.00012707243],"genre_scores_gemma":[0.99929786,0.00015329498,0.000058718455,0.000021793106,0.000013063755,0.000014589664,0.00041503523,0.0000024144738,0.000023140195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984617,0.0003995084,0.00024870283,0.00042195612,0.00027916636,0.00018906749],"domain_scores_gemma":[0.9961665,0.0005675208,0.0022100315,0.0004452725,0.00024010047,0.0003705724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013721484,0.00035915308,0.0006813032,0.0010062313,0.00040952646,0.0008224067,0.0005089299,0.00053795124,0.0008712765],"category_scores_gemma":[0.003243098,0.00042821537,0.0006257211,0.0016374275,0.0003652937,0.0004918383,0.0005161746,0.0005107465,0.00023960185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018376313,0.000024623252,0.99859244,0.000009590321,0.00008048208,0.00017115871,0.00003691727,0.000029036975,0.00008514306,0.000012760178,0.00009619114,0.000677944],"study_design_scores_gemma":[0.000046984125,0.0002539938,0.9974032,0.000018021638,0.0001238233,0.0013002424,0.00020504277,0.00028231696,0.00008171056,0.000023596978,0.00025173518,0.00000923022],"about_ca_topic_score_codex":0.0015573981,"about_ca_topic_score_gemma":0.0019406824,"teacher_disagreement_score":0.0015573981,"about_ca_system_score_codex":0.00034281643,"about_ca_system_score_gemma":0.0005300465,"threshold_uncertainty_score":0.0072566867},"labels":[],"label_agreement":null},{"id":"W4415736281","doi":"10.1177/17562864251388019","title":"Open-label study of efgartigimod in seronegative myasthenia gravis","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Argenx","keywords":"Myasthenia gravis; Disease; Clinical trial; MEDLINE; Multiple sclerosis","score_opus":0.03148259894330482,"score_gpt":0.37144689508051537,"score_spread":0.3399642961372106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415736281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947807,0.0016089668,0.0003080877,0.00014045977,0.00013763299,0.0013934011,0.0006455083,0.000054658976,0.0009305225],"genre_scores_gemma":[0.9937921,0.00088824745,0.000589894,0.00043496597,0.0003504248,0.0016040113,0.00091799436,0.000011578325,0.0014108671],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9993457,0.000322777,0.00004454159,0.000115590505,0.00007628897,0.00009509023],"domain_scores_gemma":[0.9986786,0.0003434169,0.00027326902,0.00013814068,0.00009575296,0.00047083374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017287544,0.0013758792,0.0030069607,0.00044941975,0.00039075338,0.00076213485,0.0007483128,0.0014147082,0.004089695],"category_scores_gemma":[0.0012881733,0.00044818825,0.0010603509,0.00034142635,0.0011603611,0.0010282947,0.00036638186,0.0024771506,0.0009035527],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9020249,0.048118163,0.004296754,0.00054414617,0.0008698343,0.00020351648,0.00011776407,0.0005388869,0.012870657,0.00009606473,0.0006275161,0.029691717],"study_design_scores_gemma":[0.5098727,0.47590238,0.011626845,0.000021988233,0.0002671074,0.000114362054,0.000033704087,0.0005107683,0.0007445873,0.000079180405,0.0008065533,0.000019737097],"about_ca_topic_score_codex":0.0005137601,"about_ca_topic_score_gemma":0.0010082653,"teacher_disagreement_score":0.004089695,"about_ca_system_score_codex":0.0005316812,"about_ca_system_score_gemma":0.00064873917,"threshold_uncertainty_score":0.013681352},"labels":[],"label_agreement":null},{"id":"W7116706400","doi":"10.1177/17562864251406032","title":"Regional perfusion parameters as potential indicators of parenchymal hematoma risk following reperfusion therapy for acute ischemic stroke in the extended time window","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"State Key Laboratory of Medical Neurobiology; Science and Technology Commission of Shanghai Municipality; National Natural Science Foundation of China; Shanghai Municipal Health Commission","keywords":"Reperfusion therapy; Stroke (engine); Ischemic stroke; Perfusion scanning; Parenchyma; Perfusion; Ischemia; Reperfusion injury","score_opus":0.00823023003550447,"score_gpt":0.2940993371725928,"score_spread":0.2858691071370883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116706400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99849427,0.0005619141,0.00039444325,0.000024837802,0.000004982025,0.000013184793,0.00015442503,0.0000056432805,0.00034626844],"genre_scores_gemma":[0.99950135,0.000099144774,0.00018508488,0.0000071176087,0.00000957231,0.000011534877,0.00013181518,0.0000014041785,0.00005296523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99974793,0.00008301505,0.000027690916,0.000047060188,0.000055843375,0.000038409555],"domain_scores_gemma":[0.99850595,0.0003676818,0.0007658106,0.00008532799,0.0001108896,0.00016432615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009776447,0.00028138838,0.0002910297,0.0005265787,0.000117233496,0.0004771397,0.00019884347,0.00021480127,0.0009698572],"category_scores_gemma":[0.0024022164,0.00008354725,0.00033162304,0.0004211327,0.00021326625,0.00037949506,0.000259692,0.00039951823,0.00010490989],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020098556,0.000055748344,0.98775196,0.000031715233,0.00018444272,0.00021649877,0.000043168922,0.00045226066,0.0013048113,0.000052323598,0.000076433156,0.0078206705],"study_design_scores_gemma":[0.000025303949,0.000619799,0.9964224,0.000010070669,0.00013666211,0.0005333398,0.00005049169,0.0012649412,0.0005999935,0.0001325171,0.00019714395,0.0000073298525],"about_ca_topic_score_codex":0.0006346796,"about_ca_topic_score_gemma":0.0008040108,"teacher_disagreement_score":0.0009776447,"about_ca_system_score_codex":0.00024549445,"about_ca_system_score_gemma":0.0002802179,"threshold_uncertainty_score":0.0051703453},"labels":[],"label_agreement":null},{"id":"W7117165888","doi":"10.1177/17562864251399595","title":"Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Montréal","funders":"","keywords":"Retrospective cohort study; Horizontal and vertical; Disease; Prospective cohort study; Stability (learning theory)","score_opus":0.04490933011687496,"score_gpt":0.34399487146628144,"score_spread":0.29908554134940646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117165888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99493635,0.0008365312,0.00035647623,0.000084225205,0.000010109101,0.000038336264,0.0032762347,0.000011305622,0.00045044467],"genre_scores_gemma":[0.9968353,0.00023077748,0.00022838202,0.000050044346,0.000010453922,0.00004696705,0.0025485998,0.000006221218,0.000043239696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98865557,0.0045209713,0.0024243114,0.002024847,0.0017702926,0.00060397404],"domain_scores_gemma":[0.9622691,0.0064704493,0.023971004,0.004579082,0.0018347894,0.0008755047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010750284,0.0002565452,0.00080528593,0.0011881092,0.0004570237,0.0013299438,0.0007567386,0.00043955498,0.00078530627],"category_scores_gemma":[0.021738684,0.00037816388,0.0010456936,0.0028185288,0.00048175556,0.0010426373,0.0010125176,0.00072365697,0.00022488611],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030838378,0.000021383896,0.99760926,0.000032357522,0.00025027205,0.000032478154,0.000056144632,0.00013336314,0.00003978795,0.000046077068,0.0002822829,0.0011882095],"study_design_scores_gemma":[0.00003779576,0.00017946173,0.99746346,0.00004453612,0.00025507578,0.00028949723,0.00019701953,0.0007359931,0.00012274625,0.00004708835,0.0006147532,0.000012570066],"about_ca_topic_score_codex":0.0050983718,"about_ca_topic_score_gemma":0.0048552076,"teacher_disagreement_score":0.010750284,"about_ca_system_score_codex":0.0007697997,"about_ca_system_score_gemma":0.0011103732,"threshold_uncertainty_score":0.056853592},"labels":[],"label_agreement":null}]}